Teleflex (TFX) 10-Q 30 Jul 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 28, 2015	Jul. 20, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 28, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	TFX
Entity Registrant Name	TELEFLEX INC
Entity Central Index Key	96,943
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		41,596,562

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Income Statement [Abstract]
Net revenues	$ 452,045	$ 468,105	$ 881,475	$ 906,651
Cost of goods sold	218,808	224,017	425,601	441,404
Gross profit	233,237	244,088	455,874	465,247
Selling, general and administrative expenses	142,228	146,843	281,925	287,140
Research and development expenses	13,443	14,870	26,327	28,932
Restructuring and impairment charges	580	7,623	5,028	15,403
Income from continuing operations before interest, extinguishment of debt and taxes	76,986	74,752	142,594	133,772
Interest expense	16,207	16,062	33,379	31,466
Interest income	(154)	(146)	(323)	(333)
Loss on extinguishment of debt, net	10,454	0	10,454	0
Income from continuing operations before taxes	50,479	58,836	99,084	102,639
Taxes on income from continuing operations	5,280	10,006	14,612	18,540
Income from continuing operations	45,199	48,830	84,472	84,099
Operating loss from discontinued operations	(145)	(1,594)	(644)	(1,619)
Taxes (benefit) on loss from discontinued operations	45	(469)	249	(369)
Loss from discontinued operations	(190)	(1,125)	(893)	(1,250)
Net income	45,009	47,705	83,579	82,849
Less: Income from continuing operations attributable to noncontrolling interest	446	453	664	639
Net income attributable to common shareholders	$ 44,563	$ 47,252	$ 82,915	$ 82,210
Basic:
Income from continuing operations (in dollars per share)	$ 1.08	$ 1.17	$ 2.02	$ 2.02
Loss from discontinued operations (in dollars per share)	(0.01)	(0.03)	(0.02)	(0.03)
Net income (in dollars per share)	1.07	1.14	2	1.99
Diluted:
Income from continuing operations (in dollars per share)	0.93	1.04	1.76	1.81
Loss from discontinued operations (in dollars per share)	0	(0.02)	(0.02)	(0.03)
Net income (in dollars per share)	0.93	1.02	1.74	1.78
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.68	$ 0.68
Weighted average common shares outstanding
Basic (in shares)	41,560	41,380	41,514	41,321
Diluted (in shares)	48,081	46,392	47,688	46,071
Amounts attributable to common shareholders:
Income from continuing operations, net of tax	$ 44,753	$ 48,377	$ 83,808	$ 83,460
Loss from discontinued operations, net of tax	(190)	(1,125)	(893)	(1,250)
Net income attributable to common shareholders	$ 44,563	$ 47,252	$ 82,915	$ 82,210

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Statement of Comprehensive Income [Abstract]
Net income	$ 45,009	$ 47,705	$ 83,579	$ 82,849
Other comprehensive income (loss), net of tax:
Foreign currency translation, net of tax of $(5,334), $531, $18,104 and $3,719 for the three and six month periods, respectively	21,203	1,173	(61,887)	5,290
Pension and other postretirement benefit plans adjustment, net of tax of $(399), $(206), $(1,285) and $(709) for the three and six month periods, respectively	531	618	2,437	1,242
Derivatives qualifying as hedges, net of tax of $461, $(40), $436 and $(82) for the three and six month periods, respectively	(803)	73	(759)	143
Other comprehensive income (loss), net of tax:	20,931	1,864	(60,209)	6,675
Comprehensive income	65,940	49,569	23,370	89,524
Less: comprehensive income attributable to non-controlling interest	391	455	670	707
Comprehensive income attributable to common shareholders	$ 65,549	$ 49,114	$ 22,700	$ 88,817

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Statement of Comprehensive Income [Abstract]
Foreign Currency translation tax	$ (5,334)	$ 531	$ 18,104	$ 3,719
Pension and other postretirement benefits plans adjustment, tax	(399)	(206)	(1,285)	(709)
Derivatives qualifying as hedges, tax	$ 461	$ (40)	$ 436	$ (82)

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 325,010	$ 303,236
Accounts receivable, net	286,371	273,704
Inventories, net	347,095	335,593
Prepaid expenses and other current assets	34,659	35,697
Prepaid taxes	46,008	40,256
Deferred tax assets	56,294	57,301
Assets held for sale	7,072	7,422
Total current assets	1,102,509	1,053,209
Property, plant and equipment, net	315,536	317,435
Goodwill	1,317,874	1,323,553
Intangible assets, net	1,185,517	1,216,720
Investments in affiliates	401	1,150
Deferred tax assets	1,134	1,178
Other assets	61,191	64,010
Total assets	3,984,162	3,977,255
Current liabilities
Current borrowings	415,991	368,401
Accounts payable	74,364	64,100
Accrued expenses	65,843	72,383
Current portion of contingent consideration	5,802	11,276
Payroll and benefit-related liabilities	69,564	85,442
Accrued interest	7,991	9,169
Income taxes payable	11,700	13,768
Other current liabilities	10,631	10,360
Total current liabilities	661,886	634,899
Long-term borrowings	696,000	700,000
Deferred tax liabilities	433,257	451,541
Pension and postretirement benefit liabilities	161,036	167,241
Noncurrent liability for uncertain tax provisions	50,547	50,884
Other liabilities	61,429	58,991
Total liabilities	$ 2,064,155	$ 2,063,556
Commitments and contingencies
Total common shareholders' equity	$ 1,917,779	$ 1,911,309
Noncontrolling interest	2,228	2,390
Total equity	1,920,007	1,913,699
Total liabilities and equity	$ 3,984,162	$ 3,977,255

CONDENSED CONSOLIDATED STATEME6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014
Cash Flows from Operating Activities of Continuing Operations
Net income	$ 83,579	$ 82,849
Adjustments to reconcile net income to net cash provided by operating activities:
Loss from discontinued operations	893	1,250
Depreciation expense	22,385	23,997
Amortization expense of intangible assets	29,826	32,102
Amortization expense of deferred financing costs and debt discount	8,421	7,716
Loss on extinguishment of debt, net	10,454	0
Changes in contingent consideration	(2,293)	(6,617)
Stock-based compensation	7,126	5,726
Deferred income taxes, net	625	2,811
Other	(6,301)	(2,142)
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:
Accounts receivable	(17,984)	640
Inventories	(16,895)	(16,385)
Prepaid expenses and other current assets	921	2,407
Accounts payable and accrued expenses	(2,966)	(1,731)
Income taxes receivable and payable, net	(8,203)	(12,462)
Net cash provided by operating activities from continuing operations	109,588	120,161
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment	(31,321)	(30,850)
Proceeds from sale of assets and investments	0	4,139
Payments for businesses and intangibles acquired, net of cash acquired	(37,559)	(28,535)
Investment in affiliates	0	(60)
Net cash used in investing activities from continuing operations	(68,880)	(55,306)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from new borrowings	288,100	250,000
Reduction in borrowings	(250,981)	(480,000)
Debt extinguishment, issuance and amendment fees	(8,746)	(3,275)
Net proceeds from share based compensation plans and the related tax impacts	4,843	2,391
Payments to noncontrolling interest shareholders	(832)	(1,094)
Payments for contingent consideration	(3,989)	0
Dividends	(28,234)	(28,093)
Net cash provided by (used in) financing activities from continuing operations	161	(260,071)
Cash Flows from Discontinued Operations:
Net cash used in operating activities	(1,363)	(1,531)
Net cash used in discontinued operations	(1,363)	(1,531)
Effect of exchange rate changes on cash and cash equivalents	(17,732)	2,145
Net increase (decrease) in cash and cash equivalents	21,774	(194,602)
Cash and cash equivalents at the beginning of the period	303,236	431,984
Cash and cash equivalents at the end of the period	$ 325,010	$ 237,382

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Treasury Stock	Noncontrolling Interest
Beginning Balance (in shares) at Dec. 31, 2013		43,243				2,064
Beginning Balance at Dec. 31, 2013	$ 1,916,016	$ 43,243	$ 409,338	$ 1,696,424	$ (110,855)	$ (124,623)	$ 2,489
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	82,849			82,210			639
Cash dividends (USD per share)	(28,093)			(28,093)
Other comprehensive (loss) income	6,675				6,607		68
Distributions to noncontrolling interest shareholders	(1,094)						(1,094)
Shares issued under compensation plans (in shares)		144				70
Shares issued under compensation plans	7,945	$ 144	5,237			$ 2,564
Deferred compensation (in shares)						(2)
Deferred compensation	81					$ 81
Ending Balance (in shares) at Jun. 29, 2014		43,387				1,992
Ending Balance at Jun. 29, 2014	1,984,379	$ 43,387	414,575	1,750,541	(104,248)	$ (121,978)	2,102
Beginning Balance (in shares) at Dec. 31, 2014		43,420				1,981
Beginning Balance at Dec. 31, 2014	1,913,699	$ 43,420	422,394	1,827,845	(260,895)	$ (121,455)	2,390
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	83,579			82,915			664
Cash dividends (USD per share)	(28,234)			(28,234)
Other comprehensive (loss) income	(60,209)				(60,215)		6
Distributions to noncontrolling interest shareholders	(832)						(832)
Settlements of convertible notes	2		(36)			38
Settlements of note hedges associated with convertible notes	0		71			$ (71)
Shares issued under compensation plans (in shares)		93				58
Shares issued under compensation plans	11,929	$ 93	10,290			$ 1,546
Deferred compensation (in shares)						(3)
Deferred compensation	73					$ 73
Ending Balance (in shares) at Jun. 28, 2015		43,513				1,920
Ending Balance at Jun. 28, 2015	$ 1,920,007	$ 43,513	$ 432,719	$ 1,882,526	$ (321,110)	$ (119,869)	$ 2,228

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Parenthetical) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Statement of Stockholders' Equity [Abstract]
Dividends per share (in dollars per share)	$ 0.34	$ 0.34	$ 0.68	$ 0.68

Basis of presentation

Basis of presentation	6 Months Ended
	Jun. 28, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of presentation	Note 1 — Basis of presentation The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated and its subsidiaries are prepared on the same basis as the annual consolidated financial statements. In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair statement of financial statements for interim periods in accordance with accounting principles generally accepted in the United States of America ("GAAP") and with Rule 10-01 of SEC Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed consolidated balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014 . Effective April 1, 2015, the Company reorganized certain of its businesses to better leverage the Company’s resources. As a result, the Company realigned its operating segments. See Note 14 for additional information, including information regarding changes in the composition of certain of the Company's reportable operating segments. As used in this report, the terms “we,” “us,” “our,” “Teleflex” and the “Company” mean Teleflex Incorporated and its subsidiaries, unless the context indicates otherwise. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

New accounting standards

New accounting standards	6 Months Ended
	Jun. 28, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In July 2015, the FASB deferred the effective date of the new guidance. The guidance is effective prospectively for annual periods beginning after December 15, 2017 and interim periods within those years; early application is permitted for annual periods beginning after December 15, 2016. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows and financial position. In April 2015, FASB issued guidance for the reporting of debt issuance costs within the balance sheet. Under the new guidance, debt issuance costs are to be presented in the balance sheet as a direct deduction from the associated debt liability, consistent with the presentation of a debt discount. Currently, debt issuance costs are presented as a deferred charge (i.e., an asset) on the balance sheet. In addition to providing uniform treatment for debt issuance costs and debt discounts, the guidance is consistent with other FASB guidance, which states that debt issuance costs are similar to debt discounts because they reduce the proceeds of borrowing (thereby increasing the effective interest rate) and cannot be an asset because they provide no future economic benefit. The new guidance is effective for fiscal years beginning after December 15, 2015 with early adoption permitted, and is required to be applied on a retrospective basis. The Company does not believe that the adoption of this guidance will have a material impact on the Company’s financial position. From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed above, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	6 Months Ended
	Jun. 28, 2015
Business Combinations [Abstract]
Acquisitions	Note 3 — Acquisitions The Company made the following acquisitions during 2015 (the "2015 acquisitions"), which were accounted for as business combinations: • On January 20, 2015, the Company acquired Human Medics Co., Ltd., (“Human Medics”), a distributor of medical devices and supplies primarily in the Korean market. • On March 30, 2015, the Company acquired Trintris Medical, Inc. ("Trintris"), an original equipment manufacturer (OEM) of balloons and catheters that complement the Company's OEM product portfolio. • On April 8, 2015, the Company acquired Truphatek Holdings Limited ("Truphatek"), a manufacturer of a broad range of disposable and reusable laryngoscope devices that complement the Company's anesthesia product portfolio. The Company had previously held a 6% noncontrolling interest in Truphatek. • On June 26, 2015, the Company acquired certain assets of N. Stenning & Co., Pty., Ltd. ("Stenning"), a distributor of medical devices and supplies primarily in the Australian market. As a result of the above transactions, the Company has acquired all of the common stock and voting equity interest in Human Medics, Trintris and Truphatek. The aggregate total fair value of consideration for the 2015 acquisitions is estimated to be $40.4 million , which includes initial payments of $37.8 million , $1.8 million in deferred consideration and the fair value of the Company's previously held noncontrolling equity interest in Truphatek of $1.2 million , partially offset by a $0.4 million favorable working capital adjustment. As a result of the Company's remeasurement, immediately prior to the acquisition date, of the fair value of the noncontrolling equity interest the Company previously held in Truphatek, the Company recognized a gain of $1.0 million that reduced selling, general and administrative expenses in the condensed consolidated statements of income. Transaction expenses associated with the acquisitions, which are included in selling, general and administrative expenses in the condensed consolidated statement of income were $0.7 million for the six months ended June 28, 2015 . The results of operations of the acquired businesses are included in the condensed consolidated statements of income from the acquisition date. For the three months ended June 28, 2015 , the Company recorded revenue and loss from continuing operations before taxes related to the acquired businesses of $1.8 million and $0.3 million , respectively . For the six months ended June 28, 2015 , the Company recorded revenue and loss from continuing operations before taxes related to the acquired businesses of $2.6 million and $0.9 million , respectively. Pro forma information is not presented as the operations of the acquired businesses are not significant to the overall operations of the Company. The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the 2015 acquisitions: (Dollars in thousands) Assets Current assets $ 10,364 Property, plant and equipment 2,475 Intangible assets: Intellectual property 4,067 Non-compete agreements 1,916 Customer list 8,302 Goodwill 18,928 Other assets 45 Total assets acquired 46,097 Less: Current liabilities 3,048 Deferred tax liabilities 2,477 Other liabilities 138 Liabilities assumed 5,663 Net assets acquired $ 40,434 The Company is continuing to evaluate the 2015 acquisitions. Further adjustments may be necessary as a result of the Company's assessment of additional information related to the fair values of the assets acquired and liabilities assumed, primarily deferred tax liabilities and goodwill. Among the acquired assets, intellectual property has useful lives ranging from 15 to 20 years, customer lists have useful lives ranging from 10 to 18 years and non-compete arrangements have useful lives of 5 years. The goodwill resulting from the acquisitions primarily reflects synergies expected to be realized from the integration of the acquired businesses. Goodwill and the step-up in basis of the intangible assets in connection with stock acquisitions are not deductible for tax purposes. The Company made the following acquisitions during 2014 (the "2014 acquisitions"), which were accounted for as business combinations: • On February 3, 2014, the Company acquired Mayo Healthcare Pty Limited, ("Mayo Healthcare"), a distributor of medical devices and supplies primarily in the Australian market. • On December 2, 2014, the Company acquired the assets of Mini-Lap Technologies, Inc. ("Mini-Lap"), a developer of micro-laparoscopic instrumentation that complement the Company's surgical product portfolio. The total fair value of consideration for the 2014 acquisitions was $66.3 million . The results of operations of the acquired businesses and assets are included in the consolidated statements of income from their respective acquisition dates. Pro forma information is not presented as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring and impairment ch

Restructuring and impairment charges	6 Months Ended
	Jun. 28, 2015
Restructuring and Related Activities [Abstract]
Restructuring and impairment charges	Note 4 — Restructuring and impairment charges 2015 Restructuring Plans During the first quarter 2015, the Company committed to programs associated with the reorganization of certain of its businesses as discussed in Note 14 and the consolidation of certain facilities in North America. The Company estimates that it will record aggregate pre-tax charges of $6 million to $7 million related to these programs, which represent employee termination benefits, contract termination costs and facility closure and other exit costs and will result in future cash outlays. For the three and six months ended June 28, 2015 , the Company recorded charges of $0.1 million and $4.4 million , respectively, related to these programs. As of June 28, 2015 , the Company has a reserve of $3.5 million related to these programs. 2014 Manufacturing Footprint Realignment Plan On April 28, 2014, the Board of Directors approved a restructuring plan (the “2014 Manufacturing Footprint Realignment Plan”) involving the consolidation of operations and a related reduction in workforce at certain of the Company’s facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the quarter ended June 29, 2014 and are expected to be substantially completed by the end of 2017. The Company estimates that it will incur aggregate pre-tax charges in connection with these restructuring activities of approximately $37 million to $44 million , of which an estimated $26 million to $31 million are expected to result in future cash outlays. Most of these charges are expected to be incurred prior to the end of 2016. The following table provides a summary of the Company's current cost estimates by major type of expense associated with the 2014 Manufacturing Footprint Realignment Plan: Type of expense Total estimated amount expected to be incurred Termination benefits $11 million to $13 million Facility closure and other exit costs $2 million to $3 million Accelerated depreciation charges $10 million to $11 million Other $14 million to $17 million $37 million to $44 million The Company recorded expenses of $3.6 million and $5.9 million for the three and six months ended June 28, 2015 , respectively, related to the 2014 Manufacturing Footprint Realignment Plan. Of this amount, $0.5 million and $0.7 million were recorded as restructuring expense for the three and six months ended June 28, 2015 , respectively, and $3.1 million and $5.2 million , related to accelerated depreciation and certain other transfer related costs resulting from the plan for the three and six months ended June 28, 2015 , respectively, and were included in cost of goods sold. As of June 28, 2015, the Company has incurred net aggregate restructuring and impairment charges related to the plan of $10.0 million . Additionally, as of June 28, 2015, the Company has incurred net aggregate accelerated depreciation and certain other costs in connection with the plan of $10.1 million , which were included in cost of sales. As of June 28, 2015 , the Company has a restructuring reserve of $7.5 million in connection with the plan, all of which relates to termination benefits. As the 2014 Manufacturing Footprint Realignment Plan progresses, management will reevaluate the estimated expenses set forth above, and may revise its estimates, as appropriate, consistent with generally accepted accounting principles. 2014 European Restructuring Plan In February 2014, the Company committed to a restructuring plan (the “2014 European Restructuring Plan”), which impacts certain administrative functions in Europe and involves the consolidation of operations and a related reduction in workforce at certain of the Company’s European facilities. The Company recorded no minal charges for the three and six months ended June 28, 2015 with respect to this plan. As of June 28, 2015, the Company has incurred net aggregate restructuring and impairment charges under the plan of $7.9 million . As of June 28, 2015 , the Company had a reserve of $0.4 million in connection with the 2014 European Restructuring Plan. The Company expects to complete this plan in 2015. Other 2014 Restructuring Programs In June 2014, the Company initiated programs to consolidate locations in Australia and terminate certain distributor agreements in an effort to reduce costs. As a result of these actions, the Company expects to incur aggregate restructuring and impairment charges over the term of these programs of approximately $4 million , of which, $3.6 million was incurred through June 28, 2015 . These programs include costs related to termination benefits, contract termination costs and other exit costs. As of June 28, 2015 , the Company had a reserve of $0.6 million in connection with these programs. The Company expects to complete the programs in 2015. LMA Restructuring Program In connection with the acquisition of substantially all of the assets of LMA International N.V. (the “LMA business”) in 2012, the Company commenced a program (the "LMA Restructuring Program") related to the integration of the LMA business and the Company’s other businesses. The program was focused on the closure of the LMA business’ corporate functions and the consolidation of manufacturing, sales, marketing, and distribution functions in North America, Europe and Asia. The Company incurred net aggregate restructuring and impairment charges related to the LMA Restructuring Program of $11.3 million and as of June 28, 2015 , the program is complete. 2013 Restructuring Programs In 2013, the Company initiated restructuring programs to consolidate administrative and manufacturing facilities in North America and warehouse facilities in Europe and terminate certain European distributor agreements in an effort to reduce costs. As of June 28, 2015, the Company has incurred an aggregate of $11.0 million in restructuring and impairment charges related to these restructuring programs. These programs entail costs related to termination benefits, contract termination costs and charges related to post-closing obligations associated with its acquired businesses. As of June 28, 2015 , these programs are complete. 2012 Restructuring Program In 2012, the Company identified opportunities to improve its supply chain strategy by consolidating its three North American warehouses into one centralized warehouse; and lower costs and improve operating efficiencies through the termination of certain distributor agreements in Europe, the closure of certain North American facilities and workforce reductions. As of June 28, 2015, the Company has incurred net aggregate restructuring and impairment charges of $6.3 million in connection with this program, and expects future restructuring expenses associated with the program, if any, to be nominal. As of June 28, 2015 , the Company has a reserve of $0.5 million in connection with the program. The Company expects to complete this program in 2015. Impairment Charges There were no impairment charges recorded for the three and six months ended June 28, 2015 and June 29, 2014, respectively. The restructuring and impairment charges recognized for the three and six months ended June 28, 2015 and June 29, 2014 consisted of the following: Three Months Ended June 28, 2015 (in thousands) Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total 2015 Restructuring programs $ 9 $ 63 $ 24 $ 46 $ 142 2014 Manufacturing footprint realignment plan 75 204 228 — 507 2014 European restructuring plan — — — 18 18 LMA restructuring program — — 9 — 9 2013 Restructuring programs (96 ) — — — (96 ) Total restructuring and impairment charges $ (12 ) $ 267 $ 261 $ 64 $ 580 Three Months Ended June 29, 2014 (in thousands) Termination Benefits Facility Contract Termination Costs Other Exit Costs Total 2014 Manufacturing footprint alignment $ 8,577 $ — $ — $ — $ 8,577 2014 European restructuring plan (566 ) — 305 49 (212 ) 2014 Restructuring charges 476 — 1,174 131 1,781 LMA restructuring program (29 ) (154 ) (2,759 ) — (2,942 ) 2013 Restructuring charges 317 — 57 22 396 2012 Restructuring charges (9 ) 34 — — 25 2011 Restructuring plan — (2 ) — — (2 ) Total restructuring and impairment charges $ 8,766 $ (122 ) $ (1,223 ) $ 202 $ 7,623 Six Months Ended June 28, 2015 (in thousands) Termination Benefits Facility Contract Termination Costs Other Exit Costs Total 2015 Restructuring programs $ 3,559 $ 129 $ 645 $ 47 $ 4,380 2014 Manufacturing footprint realignment plan 212 230 228 — 670 2014 European restructuring plan 9 — — 34 43 Other 2014 restructuring programs — — 49 — 49 LMA restructuring program — — (21 ) 1 (20 ) 2013 Restructuring programs (94 ) — — — (94 ) Total restructuring and impairment charges $ 3,686 $ 359 $ 901 $ 82 $ 5,028 Six Months Ended June 29, 2014 (in thousands) Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total 2014 Manufacturing footprint alignment $ 8,577 $ — $ — $ — $ 8,577 2014 European restructuring plan 7,752 — 305 49 8,106 2014 Restructuring charges 476 — 1,174 131 1,781 LMA restructuring program (29 ) (112 ) (3,231 ) — (3,372 ) 2013 Restructuring charges 485 — 57 22 564 2012 Restructuring charges (619 ) 354 — — (265 ) 2011 Restructuring plan — 12 — — 12 Total restructuring and impairment charges $ 16,642 $ 254 $ (1,695 ) $ 202 $ 15,403 Termination benefits include estimated employee retention, severance and benefit payments for terminated employees. Facility closure costs include general operating costs incurred subsequent to production shutdown as well as equipment relocation and other associated costs. Contract termination costs include costs associated with terminating existing leases and distributor agreements. Other costs include legal, outplacement and employee relocation costs and other employee-related costs. Restructuring and impairment charges by reportable operating segment for the three and six months ended June 28, 2015 and June 29, 2014 are set forth in the following table: Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Restructuring and impairment charges Vascular North America $ 520 $ 6,811 $ 2,783 $ 6,886 Anesthesia North America (2 ) 1,151 534 1,178 Surgical North America — — 246 — EMEA (43 ) (1,575 ) (75 ) 6,315 Asia 1 519 1 597 All other 104 717 1,539 427 Total restructuring and impairment charges $ 580 $ 7,623 $ 5,028 $ 15,403 In the second quarter 2015, the Company reorganized certain of its businesses and as a result realigned its operating segments. See Note 14 for additional details including information on changes in the composition of certain of the Company’s reportable operating segments.

Inventories, net

Inventories, net	6 Months Ended
	Jun. 28, 2015
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net Inventories as of June 28, 2015 and December 31, 2014 consisted of the following: June 28, 2015 December 31, 2014 (Dollars in thousands) Raw materials $ 74,387 $ 68,191 Work-in-process 60,122 58,526 Finished goods 249,044 242,750 383,553 369,467 Less: inventory reserve (36,458 ) (33,874 ) Inventories, net $ 347,095 $ 335,593

Goodwill and other intangible a

Goodwill and other intangible assets, net	6 Months Ended
	Jun. 28, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and other intangible assets, net	Note 6 — Goodwill and other intangible assets, net In the second quarter 2015, the Company reorganized certain of its businesses and as a result realigned its operating segments. Additionally, this change impacted the Company's reporting units and as a result, as of the April 1, 2015 effective date, the Company performed impairment analyses for the new reporting units by comparing the fair value of the reporting units, including goodwill, to their carrying values. The impairment analyses performed included the reallocation of the goodwill balances as a result of the changes previously noted. There were no goodwill impairment charges recorded as a result of these analyses. See Note 14 for additional information, including information on changes in the composition of certain of the Company’s reportable operating segments. The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the six months ended June 28, 2015 : Vascular North America Anesthesia North America Surgical North America EMEA Asia OEM All Other Total (Dollars in thousands) Balance as of December 31, 2014 Goodwill $ 564,177 $ 214,429 $ 250,912 $ 339,029 $ 144,712 $ — $ 142,422 $ 1,655,681 Accumulated impairment losses (219,527 ) (84,531 ) — — — — (28,070 ) (332,128 ) 344,650 129,898 250,912 339,029 144,712 — 114,352 1,323,553 Goodwill related to acquisitions — 12,473 — 1,149 4,112 1,194 — 18,928 Translation adjustment 88 (351 ) — (20,550 ) (2,636 ) — (1,158 ) (24,607 ) Balance at June 28, 2015 Goodwill 564,265 226,551 250,912 319,628 146,188 1,194 141,264 1,650,002 Accumulated impairment losses (219,527 ) (84,531 ) — — — — (28,070 ) (332,128 ) $ 344,738 $ 142,020 $ 250,912 $ 319,628 $ 146,188 $ 1,194 $ 113,194 $ 1,317,874 The following table provides information as of June 28, 2015 and December 31, 2014 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net: Gross Carrying Amount Accumulated Amortization June 28, 2015 December 31, 2014 June 28, 2015 December 31, 2014 (Dollars in thousands) Customer relationships $ 625,603 $ 624,574 $ (203,458 ) $ (192,876 ) In-process research and development 41,000 68,694 — — Intellectual property 495,076 467,068 (159,643 ) (146,131 ) Distribution rights 15,660 16,101 (13,969 ) (14,243 ) Trade names 388,322 396,269 (4,990 ) (2,764 ) Non-compete agreements 2,253 337 (337 ) (309 ) $ 1,567,914 $ 1,573,043 $ (382,397 ) $ (356,323 ) In May 2012, the Company acquired Semprus BioSciences ("Semprus"), a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications. The Company experienced difficulties with respect to the development of the Semprus technology, and devoted further research and testing towards attempting to resolve the issue. As a result of these efforts, the Company believes it has resolved the issue and is focused on seeking regulatory approval and engaging in additional research and development efforts to achieve commercialization of this technology. Despite this progress, significant challenges to commercialization of the Semprus technology remain, and the Company ultimately may find it necessary to recognize impairment charges with respect to the related assets, which could be material. As of June 28, 2015 , the Company has in-process research and development ("IPR&D") intangible assets of $41.0 million related to this investment which are recorded in intangible assets, net. Amortization expense related to intangible assets was $15.1 million and $16.1 million for the three months ended June 28, 2015 and June 29, 2014 , respectively, and $29.8 million and $32.1 million for the six months ended June 28, 2015 and June 29, 2014 , respectively. Estimated annual amortization expense for the remainder of 2015 and the next five succeeding years is as follows (dollars in thousands): 2015 $ 29,200 2016 62,800 2017 62,300 2018 62,100 2019 61,900 2020 61,700

Borrowings

Borrowings	6 Months Ended
	Jun. 28, 2015
Debt Disclosure [Abstract]
Borrowings	Note 7 — Borrowings The Company's borrowings at June 28, 2015 and December 31, 2014 are as follows: June 28, 2015 December 31, 2014 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 1.94% at June 28, 2015, due 2018 $ 446,000 $ 200,000 3.875% Convertible Senior Subordinated Notes due 2017 399,817 399,898 6.875% Senior Subordinated Notes due 2019 — 250,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 0.94% at June 28, 2015 45,900 4,700 1,141,717 1,104,598 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (29,726 ) (36,197 ) 1,111,991 1,068,401 Current borrowings (415,991 ) (368,401 ) Long-term borrowings $ 696,000 $ 700,000 Classification of 3.875% Convertible Notes as a Current Liability The Company's 3.875% Convertible Notes due 2017 (the "Convertible Notes") are convertible into shares of the Company's common stock at the option of the holder upon the occurrence of any of the following circumstances (i) during any fiscal quarter, if the last reported sale price of the Company’s common stock for at least 20 trading days during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price on each applicable trading day; or (ii) during the 5 business day period after any 5 consecutive trading day period (the “measurement period”) in which the trading price per $1,000 principal amount of Convertible Notes is less than 98% of the product of the last reported sale price of the common stock and the applicable conversion rate on each trading day during the measurement period; or (iii) upon the occurrence of specified corporate events; or (iv) at any time on or after May 1, 2017 up to and including July 28, 2017 . The Convertible Notes are convertible at a conversion rate of 16.3084 shares of common stock per $1,000 principal amount of Convertible Notes, which is equivalent to a conversion price of approximately $61.32 per share. The conversion rate is subject to adjustment upon certain events. Upon conversion, the Company’s conversion obligation may be satisfied, at the Company’s option, in shares of common stock, cash or a combination of cash and shares of common stock. The Company has elected a net-settlement method to satisfy its conversion obligation. Under the net-settlement method, the Company will settle the $1,000 principal amount of the Convertible Notes in cash and settle the excess conversion value in shares, plus cash in lieu of fractional shares. Since the fourth quarter 2013, the Company's last reported sale price has exceeded the 130% threshold described above and accordingly the Convertible Notes have been classified as a current liability as of June 28, 2015 and December 31, 2014 . The determination of whether or not the Convertible Notes are convertible as described above is made each quarter until maturity, conversion or repurchase. Consequently, it is possible that the Convertible Notes may not be convertible in one or more future quarters, in which case the Convertible Notes would again be classified as long-term debt, unless one of the other conversion contingencies described above were to be satisfied. While the Company believes it has sufficient liquidity to repay the principal amount due through a combination of utilizing its existing cash on hand and accessing its credit facility, the Company's use of these funds could adversely affect its results of operations and liquidity. Exchange Offer for the 5.25% Senior Notes due 2024 On March 30, 2015, the Company commenced an exchange offer with respect to the 5.25% Senior Notes due 2024 (the "Old 2024 Notes"), under which the holders of the Old 2024 Notes, which were initially issued in a private placement, were provided an opportunity to exchange the Old 2024 Notes for new notes (the "New 2024 Notes") issued pursuant to a registration statement under the Securities Act of 1933. Other than the absence of registration rights for the holders of the New 2024 Notes, the terms of the New 2024 Notes are essentially identical to the terms of the Old 2024 Notes.The exchange offer was completed on April 24, 2015; all of the holders of the Old 2024 Notes exchanged their Old 2024 Notes for New 2024 Notes. Redemption of 6.875% Senior Subordinated Notes due 2019 On June 1, 2015, the Company prepaid the $250 million aggregate principal amount of 6.875% Senior Subordinated Notes due 2019 (the “2019 Notes”). In addition to its prepayment of principal, the Company paid the holders of the 2019 Notes an $8.6 million prepayment make-whole amount plus accrued and unpaid interest. The Company recorded the prepayment make-whole amount and a $1.9 million write-off of unamortized debt issuance costs as a loss on extinguishment of debt in the condensed consolidated statement of income in the second quarter 2015. The Company used $246.0 million in borrowings under its revolving credit facility, $12.1 million in borrowings under its securitization program and available cash to fund the prepayment of the 2019 Notes. Repayment of Revolving Credit Facility Borrowings On July 29, 2015, the Company repaid $50 million of outstanding borrowings under its revolving credit facility with available cash. Fair Value of Long-Term Debt The carrying amount of current and long-term borrowings as reported in the condensed consolidated balance sheet as of June 28, 2015 is $1,112.0 million . To determine the fair value of its debt, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of June 28, 2015 and December 31, 2014, categorized by the level of inputs within the fair value hierarchy used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2014 for further information): June 28, 2015 December 31, 2014 (Dollars in thousands) Level 1 $ 878,638 $ 1,024,806 Level 2 735,924 455,222 Total $ 1,614,562 $ 1,480,028

Financial instruments

Financial instruments	6 Months Ended
	Jun. 28, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial instruments	Note 8 — Financial instruments The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts are used to manage foreign currency transaction exposure. These derivative instruments are designated as cash flow hedges and are recorded on the condensed consolidated balance sheet at fair market value. The effective portion of the gains or losses on derivatives is reported as a component of other comprehensive (loss) income and thereafter is recognized in the condensed consolidated statement of income in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness, if any, are recognized in the condensed consolidated statement of income in the period in which such gains and losses occur. The following table presents the location and fair value of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of June 28, 2015 and December 31, 2014 : June 28, 2015 December 31, 2014 Fair Value Fair Value (Dollars in thousands) Asset derivatives: Foreign currency forward contracts: Prepaid expenses and other current assets $ 419 $ — Total asset derivatives $ 419 $ — Liability derivatives: Foreign currency forward contracts: Other current liabilities $ 1,808 $ — Total liability derivatives $ 1,808 $ — The total notional amount for all open foreign currency forward contracts as of June 28, 2015 is $99.8 million . All open foreign currency forward contracts as of June 28, 2015 have durations of nine months or less. As of December 31, 2014, the Company had no open foreign currency forward contracts. The following table provides information as to the gains attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (loss) (“OCI”) for the three and six months ended June 28, 2015 and June 29, 2014 : After Tax Gain (Loss) Recognized in OCI Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Foreign currency forward contracts $ (803 ) $ 73 $ (759 ) $ 143 Total $ (803 ) $ 73 $ (759 ) $ 143 See Note 10 for information on the location in the condensed consolidated statements of income and amount of gains attributable to derivatives that were reclassified from accumulated other comprehensive (loss) income (“AOCI”) to expense (income), net of tax. There was no ineffectiveness related to the Company’s derivatives during the three and six months ended June 28, 2015 and June 29, 2014 . Based on foreign currency exchange rates at June 28, 2015 , approximately $0.8 million of unrealized gains, net of tax, within AOCI are expected to be reclassified from AOCI to the condensed consolidated statement of income during the remainder of 2015. However, the actual amount reclassified from AOCI could vary due to future changes in exchange rates. Concentration of Credit Risk Concentrations of credit risk with respect to trade accounts receivable is generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries which are subject to payment delays. Payment is dependent upon the creditworthiness of those countries’ and the financial stability of their economies. In the ordinary course of business, the Company grants non-interest bearing trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all of its customer relationships, (ii) performs ongoing credit evaluations of its customers’ financial condition, (iii) monitors the payment history and aging of its customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance. An allowance for doubtful accounts is maintained for accounts receivable based on the Company’s historical collection experience and expected collectability of the accounts receivable, considering the period an account is outstanding, the financial position of the customer and information provided by credit rating services. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. The allowance for doubtful accounts was $9.2 million and $8.8 million at June 28, 2015 and December 31, 2014 , respectively. The current portion of the allowance for doubtful accounts at June 28, 2015 and December 31, 2014 of $2.7 million and $2.4 million , respectively, are reflected in accounts receivable, net. The allowance for doubtful accounts on receivables outstanding for greater than one year at June 28, 2015 and December 31, 2014 of $6.5 million and $6.4 million , respectively, are reflected in other assets. In light of the disruptions in global economic markets in recent years, the Company instituted enhanced measures, within countries where the Company has collectability concerns, to facilitate customer-by-customer risk assessment when estimating the allowance for doubtful accounts. Such measures include, among others, monthly credit control committee meetings, at which customer credit risks are identified after review of, among other things, accounts that exceed specified credit limits, payment delinquencies and other customer issues. In addition, for some of the Company’s non-government customers, the Company instituted measures designed to reduce its risk exposures, including issuing dunning letters, reducing credit limits, requiring that payments accompany orders and instituting legal action with respect to delinquent accounts. With respect to government customers, the Company evaluates receivables for potential collection risks associated with the availability of government funding and reimbursement practices. Certain of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided, raising collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal. As a result, the Company increased the allowance for doubtful accounts related to these customers. If the financial condition of these customers or the healthcare systems in these countries deteriorate to the extent that the ability of an increasing number of customers to satisfy their payment obligations is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for customers in Greece, Italy, Spain and Portugal and the percentage of the Company’s total net current and long-term accounts receivable represented by the net current and long-term accounts receivable for customers in those countries at June 28, 2015 and December 31, 2014 are as follows: June 28, 2015 December 31, 2014 (Dollars in thousands) Current and long-term accounts receivable (net of allowances of $7.7 million and $8.1 million at June 28, 2015 and December 31, 2014, respectively) in Greece, Italy, Spain and Portugal (1) $ 76,384 $ 76,190 Percentage of total net current and long-term accounts receivable - Greece, Italy, Spain and Portugal 26.5 % 27.3 % (1) The long-term portion of accounts receivable, net from customers in Greece, Italy, Spain and Portugal at June 28, 2015 and December 31, 2014 was $9.1 million and $11.3 million , respectively, and is reported on the condensed consolidated balance sheet in other assets. For the six months ended June 28, 2015 and June 29, 2014 , net revenues from customers in Greece, Italy, Spain and Portugal were $66.2 million and $79.6 million , respectively.

Fair value measurement

Fair value measurement	6 Months Ended
	Jun. 28, 2015
Fair Value Disclosures [Abstract]
Fair value measurement	Note 9 — Fair value measurement For a description of the fair value hierarchy, see Note 10 to the Company’s 2014 consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2014 . The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of June 28, 2015 and December 31, 2014 : Total carrying Quoted prices in active markets (Level 1) Significant other Significant (Dollars in thousands) Investments in marketable securities $ 6,960 $ 6,960 $ — $ — Derivative assets 419 — 419 — Derivative liabilities 1,808 — 1,808 — Contingent consideration liabilities 27,150 — — 27,150 Total carrying Quoted prices in active markets (Level 1) Significant other Significant (Dollars in thousands) Investments in marketable securities $ 6,863 $ 6,863 $ — $ — Contingent consideration liabilities 33,433 — — 33,433 There were no transfers of financial assets or liabilities reported at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the six months ended June 28, 2015 . The following table provides information regarding changes, during the six months ended June 28, 2015, in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions: Contingent consideration 2015 (Dollars in thousands) Balance - December 31, 2014 $ 33,433 Payment (4,000 ) Revaluations (2,283 ) Balance - June 28, 2015 $ 27,150 The Company reduced contingent consideration liabilities and selling, general and administrative expense by $3.0 million for the three and six months ended June 28, 2015 after determining that relevant conditions for the payment of certain contingent consideration would not be satisfied. This reduction is included in revaluations in the preceding table. Valuation Techniques The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to satisfy benefit obligations under Company benefit plans and other arrangements. The investment assets of the trust are valued using quoted market prices. The Company’s financial assets and liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage currency transaction exposure. The Company measures the fair value of the foreign currency forward contracts by calculating the amount required to enter into offsetting contracts with similar remaining maturities, based on quoted market prices, and taking into account the creditworthiness of the counterparties. The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company accounts for contingent consideration in accordance with applicable accounting guidance related to business combinations. In connection with several of its acquisitions, the Company agreed to pay contingent consideration upon the achievement of specified objectives, including receipt of regulatory approvals, achievement of sales targets and, in some instances, the passage of time, and recorded contingent consideration liabilities at the time of the acquisitions. The Company determines the fair value of the liabilities for contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant inputs not observable in the market and, therefore, represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration liability associated with future payments under contingent consideration arrangements is based on several factors including: l estimated cash flows projected from the success of market launches; l the estimated time and resources needed to complete the development of acquired technologies; l the uncertainty of obtaining regulatory approvals within the required time periods; and l the risk adjusted discount rate for fair value measurement. In connection with the Company's contingent consideration arrangements, the Company estimates that it will make payments in 2015 through 2029. As of June 28, 2015 , the range of undiscounted amounts the Company could be required to pay under contingent consideration arrangements is between $11.0 million and $64.0 million . The Company is required to reevaluate the fair value of contingent consideration each reporting period based on new developments and record changes in fair value until such consideration is satisfied through payment upon the achievement of the specified objectives or is no longer payable due to failure to achieve the specified objectives. The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of June 28, 2015 : Valuation Technique Unobservable Input Range (Weighted Average) Contingent consideration Discounted cash flow Discount rate 1.6% - 10% (7.7%) Probability of payment 0% - 100% (57.3%) As of June 28, 2015 , the Company recorded $27.2 million of total liabilities for contingent consideration, of which $5.8 million and $21.4 million were recorded as the current portion of contingent consideration and other liabilities, respectively, in the condensed consolidated balance sheet.

Changes in shareholders' equity

Changes in shareholders' equity Changes in shareholders' equity	6 Months Ended
	Jun. 28, 2015
Equity [Abstract]
Changes in shareholders' equity	Changes in shareholders’ equity Basic earnings per share is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed in the same manner except that the weighted average number of shares is increased to include dilutive securities. The following table provides a reconciliation of basic to diluted weighted average shares outstanding: Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Shares in thousands) Basic 41,560 41,380 41,514 41,321 Dilutive effect of share-based awards 473 413 470 442 Dilutive effect of 3.875% Convertible Notes and warrants 6,048 4,599 5,704 4,308 Diluted 48,081 46,392 47,688 46,071 Weighted average shares that were antidilutive and therefore not included in the calculation of earnings per share were approximately 5.6 million and 5.7 million for the three and six months ended June 28, 2015 , respectively, and approximately 6.4 million and 6.5 million for the three and six months ended June 29, 2014 , respectively. During periods in which the average market price of the Company's common stock is above the applicable conversion price of the Convertible Notes, or $61.32 per share, the impact of conversion would be dilutive and the dilutive effect of conversion of the Convertible Notes is reflected in diluted earnings per share. As described in Note 7, the Company has elected the net settlement method of accounting for these conversions, under which the Company will settle the principal amount of the Convertible Notes in cash, and settle the excess conversion value in shares. As a result, in these periods, under the treasury stock method, the Company calculates the number of shares issuable under the terms of the Convertible Notes based on the average market price of the stock during the period, and includes that number in the total diluted shares outstanding for the period. In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge economically reduces the dilutive impact of the Convertible Notes. However, applicable accounting guidance requires the Company to separately analyze the impact of the warrant agreements on diluted weighted average shares outstanding, while excluding the impact of the convertible note hedge agreements because it would be anti-dilutive. The reductions in diluted shares that would result from including the anti-dilutive impact of the convertible note hedges would have been 3.3 million and 3.2 million for the three and six months ended June 28, 2015 , respectively, and 2.7 million and 2.6 million for the three and six months ended June 29, 2014 , respectively. The treasury stock method is applied when the warrants are in-the-money and assumes the proceeds from the exercise of the warrants are used to repurchase shares based on the average stock price during the period. The exercise price of the warrants is approximately $74.65 per share of common stock. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 2.7 million and 2.5 million for the three and six months ended June 28, 2015 , respectively, and 1.9 million and 1.7 million for the three and six months ended June 29, 2014 , respectively. In 2007, the Company’s Board of Directors authorized the repurchase of up to $300 million of outstanding Company common stock. Repurchases of Company stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and the Company’s ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generation from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under the Company’s senior credit agreements, the Company is subject to certain restrictions relating to its ability to repurchase shares in the event the Company’s consolidated leverage ratio (generally, the ratio of Consolidated Total Indebtedness to Consolidated EBITDA, as defined in the senior credit agreements) exceeds certain levels, which may limit the Company’s ability to repurchase shares under this Board authorization. Through June 28, 2015 , no shares have been purchased under this Board authorization. The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the six months ended June 28, 2015 and June 29, 2014 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2014 $ — $ (141,744 ) $ (119,151 ) $ (260,895 ) Other comprehensive income (loss) before reclassifications (922 ) 300 (61,893 ) (62,515 ) Amounts reclassified from accumulated other comprehensive (loss) income 163 2,137 — 2,300 Net current-period other comprehensive income (loss) (759 ) 2,437 (61,893 ) (60,215 ) Balance at June 28, 2015 $ (759 ) $ (139,307 ) $ (181,044 ) $ (321,110 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2013 $ — $ (97,037 ) $ (13,818 ) $ (110,855 ) Other comprehensive income (loss) before reclassifications 233 (256 ) 5,222 5,199 Amounts reclassified from accumulated other comprehensive (loss) income (90 ) 1,498 — 1,408 Net current-period other comprehensive income 143 1,242 5,222 6,607 Balance at June 29, 2014 $ 143 $ (95,795 ) $ (8,596 ) $ (104,248 ) The following table provides information relating to the reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended June 28, 2015 and June 29, 2014 : Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ 472 $ (52 ) $ 263 $ (129 ) Total before tax 472 (52 ) 263 (129 ) Tax benefit (110 ) 5 (100 ) 39 Net of tax $ 362 $ (47 ) $ 163 $ (90 ) Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,605 $ 1,103 $ 3,211 $ 2,205 Prior-service costs(1) — (6 ) — (11 ) Total before tax 1,605 1,097 3,211 2,194 Tax expense (564 ) (382 ) (1,074 ) (696 ) Net of tax $ 1,041 $ 715 $ 2,137 $ 1,498 Total reclassifications, net of tax $ 1,403 $ 668 $ 2,300 $ 1,408 (1) These accumulated other comprehensive income (loss) components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continuing

Taxes on income from continuing operations	6 Months Ended
	Jun. 28, 2015
Income Tax Disclosure [Abstract]
Taxes on income from continuing operations	Taxes on income from continuing operations The effective income tax rates for the three and six months ended June 28, 2015 and June 29, 2014 are as follows: Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 Effective income tax rate 10.5% 17.0% 14.7% 18.1% The effective income tax rate for the three and six months ended June 28, 2015 was 10.5% and 14.7% , respectively, and 17.0% and 18.1% for the three and six months ended June 29, 2014 , respectively. The effective tax rate for the three and six months ended June 28, 2015 benefited from a shift in the mix of taxable income to jurisdictions with lower statutory tax rates.

Pension and other postretiremen

Pension and other postretirement benefits	6 Months Ended
	Jun. 28, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and other postretirement benefits	Pension and other postretirement benefits The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. The Company’s funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of June 28, 2015 , the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, other than certain postretirement benefit plans covering employees subject to a collective bargaining agreement, are frozen. The Company and certain of its subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The associated plans are unfunded and approved claims are paid from Company funds. Net benefit cost of pension and postretirement benefit plans consisted of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Service cost $ 469 $ 447 $ 107 $ 138 $ 940 $ 897 $ 214 $ 276 Interest cost 4,485 4,486 $ 511 596 8,971 8,969 1,023 1,193 Expected return on plan assets (6,427 ) (6,264 ) $ — — (12,852 ) (12,524 ) — — Net amortization and deferral 1,528 1,070 $ 78 27 3,058 2,141 155 53 Net benefit expense (income) $ 55 $ (261 ) $ 696 $ 761 $ 117 $ (517 ) $ 1,392 $ 1,522 The Company’s pension contributions are expected to be approximately $2.9 million during 2015, of which $0.5 million and $1.7 million were contributed during the three and six months ended June 28, 2015 , respectively.

Commitments and contingent liab

Commitments and contingent liabilities	6 Months Ended
	Jun. 28, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingent liabilities	Commitments and contingent liabilities Operating leases: The Company uses various leased facilities and equipment in its operations. Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At June 28, 2015 the Company has recorded $0.9 million and $6.8 million , in accrued liabilities and other liabilities, respectively, relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of June 28, 2015 . The time frame over which the accrued amounts may be paid out, based on past history, is estimated to be 15 - 20 years. Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. As of June 28, 2015 , the Company has recorded accrued liabilities of $2.6 million in connection with such contingencies, representing its best estimate of the cost within the range of estimated possible losses that will be incurred to resolve these matters. Of the amount accrued as of June 28, 2015 , $1.5 million pertains to discontinued operations. In 2006, the Company was named as a defendant in a wrongful death product liability lawsuit filed in the Louisiana State District Court for the Parish of Calcasieu, involving a product manufactured by the Company’s former marine business. In September 2014, the case was tried before a jury, which returned a verdict in favor of the Company. The plaintiff subsequently filed a motion for a new trial, which was granted, and the case was re-tried before a jury in December 2014. On December 5, 2014, the jury returned a verdict in favor of the plaintiff, awarding $0.1 million in compensatory damages and $23.0 million in punitive damages, plus pre- and post-judgment interest on the compensatory damages and post-judgment interest on the punitive damages. The Company's post-trial motions seeking to overturn the verdict or reduce the amount of damages were denied in June 2015. The Company intends to appeal the verdict to the Louisiana Court of Appeal. As of June 28, 2015 , the Company has accrued a liability representing its best estimate of any probable loss associated with this matter, which is included in the Company’s accrued liabilities for litigation matters relating to discontinued operations discussed in the preceding paragraph. The Company believes that any liability arising from this matter in excess of $10.0 million will be covered by the Company’s product liability insurance. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that the outcome of any outstanding litigation and claims is likely to be, individually or in the aggregate, material to its business, financial condition, results of operations or liquidity. However, in the event of unexpected further developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may be materially adverse to the Company’s business, financial condition, results of operations or liquidity. Legal costs such as outside counsel fees and expenses are charged to selling, general and administrative expenses in the period incurred. Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various taxing authorities. As of June 28, 2015 , the most significant tax examinations in process are in Austria, Canada, Germany and the United States. In conjunction with these examinations and as a regular and routine practice, the Company may establish reserves or adjust existing reserves with respect to uncertain tax positions. Accordingly, developments occurring with respect to these examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results. Other: The Company has various purchase commitments for materials, supplies and items of permanent investment incident to the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Business segment information

Business segment information	6 Months Ended
	Jun. 28, 2015
Segment Reporting [Abstract]
Business segment information	Business segment information An operating segment is a component of the Company (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The Company does not evaluate its operating segments using discrete asset information. Effective April 1, 2015, the Company reorganized certain of its businesses to better leverage the Company’s resources. As a result, the Company realigned its operating segments. Specifically, the Company's Anesthesia/Respiratory North America operating segment was divided into two operating segments, Anesthesia North America and Respiratory North America. Additionally, the businesses comprising the Company's former Specialty operating segment (which was not a reportable segment and, therefore, was included in the "All other" category in the Company's presentation of segment information) were transferred to the Anesthesia North America, Vascular North America and Respiratory North America operating segments. As a result of the operating segment changes described above, the Company has the following six reportable operating segments: Vascular North America, Anesthesia North America, Surgical North America, EMEA, Asia and OEM. In connection with the presentation of segment information, the Company will continue to present certain operating segments, which, effective April 1, 2015, include, among others, the Respiratory North America operating segment, in the “All other” category. All prior comparative periods presented in this report have been restated to reflect these changes. The Company’s reportable segments, other than the Original Equipment Manufacturer and Development Services ("OEM") segment, design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and generally serve two end markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Company’s OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. The following tables present the Company’s segment results for the three and six months ended June 28, 2015 and June 29, 2014 : Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Revenue Vascular North America $ 81,165 $ 77,203 $ 161,931 $ 152,062 Anesthesia North America 45,579 45,730 91,028 88,982 Surgical North America 40,520 37,969 78,579 73,200 EMEA 129,132 154,670 258,414 304,915 Asia 62,042 62,539 110,571 112,141 OEM 37,918 36,610 72,633 69,792 All other 55,689 53,384 108,319 105,559 Consolidated net revenues $ 452,045 $ 468,105 $ 881,475 $ 906,651 Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Operating profit Vascular North America $ 17,055 $ 13,544 $ 32,805 $ 25,709 Anesthesia North America 11,434 8,399 21,394 15,364 Surgical North America 14,315 14,366 26,642 24,914 EMEA 19,343 30,080 45,678 56,961 Asia 18,951 17,096 27,097 29,933 OEM 8,366 8,296 16,409 14,900 All other 6,855 4,693 9,948 10,410 Total segment operating profit (1) 96,319 96,474 179,973 178,191 Unallocated expenses (2) (19,333 ) (21,722 ) (37,379 ) (44,419 ) Income from continuing operations before interest, extinguishment of debt and taxes $ 76,986 $ 74,752 $ 142,594 $ 133,772 (1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and impairment charges. Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Depreciation and amortization Vascular North America $ 9,265 $ 9,061 $ 18,413 $ 17,932 Anesthesia North America 1,552 3,111 3,194 6,355 Surgical North America 2,348 1,666 4,826 4,035 EMEA 8,342 9,673 16,240 18,610 Asia 3,010 2,305 5,408 4,143 OEM 1,704 1,608 3,371 3,064 All other 4,561 4,978 9,180 9,676 Consolidated depreciation and amortization $ 30,782 $ 32,402 $ 60,632 $ 63,815 Geographic data The following table provides total net revenues for the three months ended June 28, 2015 and June 29, 2014 and total net property, plant and equipment by geographic region as of June 28, 2015 and December 31, 2014 : Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Net revenue (based on selling location) United States $ 238,518 $ 228,349 $ 469,724 $ 444,810 Other Americas 15,122 15,187 28,563 29,959 Europe 143,692 174,193 284,375 342,967 All other 54,713 50,376 98,813 88,915 $ 452,045 $ 468,105 $ 881,475 $ 906,651 June 28, 2015 December 31, 2014 (Dollars in thousands) Net property, plant and equipment United States $ 177,772 $ 174,893 Malaysia 35,594 36,427 Czech Republic 33,612 35,655 All other 68,558 70,460 $ 315,536 $ 317,435

Condensed consolidating guarant

Condensed consolidating guarantor financial information	6 Months Ended
	Jun. 28, 2015
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed consolidating guarantor financial information	Condensed consolidating guarantor financial information In April 2015, pursuant to an exchange offer registered under the Securities Act of 1933, Teleflex Incorporated (referred to below as “Parent Company”) exchanged $250 million of its 5.25% Senior Notes due 2024 for a like principal amount of substantially identical notes that it issued in a private placement in May 2014. The notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income (loss) for the three and six months ended June 28, 2015 and June 29, 2014 , condensed consolidating balance sheets as of June 28, 2015 and December 31, 2014 and condensed consolidating statements of cash flows for the six months ended June 28, 2015 and June 29, 2014 , provide consolidated information for: a. Parent Company, the issuer of the guaranteed obligations; b. Guarantor Subsidiaries, on a combined basis; c. Non-guarantor subsidiaries, on a combined basis; and d. Parent Company and its subsidiaries on a consolidated basis. The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidated financial information, except for the use by the Parent Company and Guarantor Subsidiaries of the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation. Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-guarantor subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries. The condensed consolidating statement of cash flows for the Non-guarantor subsidiaries and eliminations for the six months ended June 29, 2014 have been revised to properly reflect that intercompany dividends paid and intercompany dividends received were between Non-guarantor subsidiaries. Previously, intercompany dividends paid and received among Non-guarantor subsidiaries were presented on a gross basis resulting in the overstatement or understatement of cash flows from operations, investing and financing activities. To eliminate this error, the condensed consolidating statement of cash flows for the six months ended June 29, 2014 have been revised as follows: In the Non-guarantor subsidiaries column, net cash (used in) provided by operating activities from continuing operations has been changed from ($33,864) to ($105,302) , intercompany dividends received (within cash flows from investing activities of continuing operations) has been changed from $229,782 to $0 and intercompany dividends paid (within cash flows from financing activities of continuing operations) changed from ($303,827) to ($3,135) . In the eliminations column, net cash (used in) provided by operating activities from continuing operations changed from ($74,045) to ($3,135) , intercompany dividends received changed from ($229,782) to $0 and intercompany dividends paid changed from $303,827 to $3,135 . The Company also made revisions to the classification of certain balances related to intercompany transactions in the condensed consolidating statements of income and comprehensive income (loss) for the three and six months ended June 29, 2014 and the condensed consolidating balance sheet at December 31, 2014 as well as the condensed consolidating statement of cash flows for the six months ended June 29, 2014 . These revisions, individually and in the aggregate, had no impact on the consolidated results of the Company and are not material to the condensed consolidating guarantor financial information for any of the previously filed periods. The Company will revise its condensed consolidated guarantor financial information for the interim periods ended September 28, 2014 and March 29, 2015 in Forms 10-Q to be filed for the fiscal quarters ending September 27, 2015 and March 27, 2016, respectively, and will revise its condensed consolidated guarantor financial information for the annual periods ended December 31, 2014 and 2013 in its Form 10-K to be filed for the fiscal year ending December 31, 2015. TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) Three Months Ended June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 269,703 $ 276,258 $ (93,916 ) $ 452,045 Cost of goods sold — 158,718 152,355 (92,265 ) 218,808 Gross profit — 110,985 123,903 (1,651 ) 233,237 Selling, general and administrative expenses 8,663 82,844 50,964 (243 ) 142,228 Research and development expenses — 4,894 8,549 — 13,443 Restructuring and impairment charges — 591 (11 ) — 580 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (8,663 ) 22,656 64,401 (1,408 ) 76,986 Interest, net 33,358 (18,565 ) 1,260 — 16,053 Loss on extinguishment of debt, net 10,454 — — — 10,454 (Loss) income from continuing operations before taxes (52,475 ) 41,221 63,141 (1,408 ) 50,479 (Benefit) taxes on income from continuing operations (17,941 ) 14,917 8,463 (159 ) 5,280 Equity in net income of consolidated subsidiaries 79,246 51,964 122 (131,332 ) — Income from continuing operations 44,712 78,268 54,800 (132,581 ) 45,199 Operating loss from discontinued operations (145 ) — — — (145 ) Taxes on loss from discontinued operations 4 — 41 — 45 Loss from discontinued operations (149 ) — (41 ) — (190 ) Net income 44,563 78,268 54,759 (132,581 ) 45,009 Less: Income from continuing operations attributable to noncontrolling interests — — 446 — 446 Net income attributable to common shareholders 44,563 78,268 54,313 (132,581 ) 44,563 Other comprehensive income attributable to common shareholders 20,986 45,015 24,340 (69,355 ) 20,986 Comprehensive income attributable to common shareholders $ 65,549 $ 123,283 $ 78,653 $ (201,936 ) $ 65,549 Three Months Ended June 29, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 290,280 $ 317,651 $ (139,826 ) $ 468,105 Cost of goods sold — 176,028 177,009 (129,020 ) 224,017 Gross profit — 114,252 140,642 (10,806 ) 244,088 Selling, general and administrative expenses 11,025 76,575 59,135 108 146,843 Research and development expenses — 12,885 1,985 — 14,870 Restructuring and impairment charges — 8,679 (1,056 ) — 7,623 (Loss) income from continuing operations before interest and taxes (11,025 ) 16,113 80,578 (10,914 ) 74,752 Interest, net 35,155 (20,740 ) 1,501 — 15,916 (Loss) income from continuing operations before taxes (46,180 ) 36,853 79,077 (10,914 ) 58,836 (Benefit) taxes on income from continuing operations (15,710 ) 13,535 14,344 (2,163 ) 10,006 Equity in net income of consolidated subsidiaries 78,802 57,250 98 (136,150 ) — Income from continuing operations 48,332 80,568 64,831 (144,901 ) 48,830 Operating loss from discontinued operations (1,594 ) — — — (1,594 ) (Benefit) taxes on loss from discontinued operations (514 ) — 45 — (469 ) Loss from discontinued operations (1,080 ) — (45 ) — (1,125 ) Net income 47,252 80,568 64,786 (144,901 ) 47,705 Less: Income from continuing operations attributable to noncontrolling interests — — 453 — 453 Net income attributable to common shareholders 47,252 80,568 64,333 (144,901 ) 47,252 Other comprehensive income (loss) attributable to common shareholders 1,862 (2,607 ) (5,984 ) 8,591 1,862 Comprehensive income attributable to common shareholders $ 49,114 $ 77,961 $ 58,349 $ (136,310 ) $ 49,114 Six Months Ended June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 533,864 $ 535,159 $ (187,548 ) $ 881,475 Cost of goods sold — 317,044 289,973 (181,416 ) 425,601 Gross profit — 216,820 245,186 (6,132 ) 455,874 Selling, general and administrative expenses 20,115 167,112 94,781 (83 ) 281,925 Research and development expenses — 16,021 10,306 — 26,327 Restructuring and impairment charges — 4,330 698 — 5,028 (Loss) income from continuing operations before interest, and taxes (20,115 ) 29,357 139,401 (6,049 ) 142,594 Interest, net 67,718 (37,134 ) 2,472 — 33,056 Loss on extinguishment of debt, net 10,454 — — — 10,454 (Loss) income from continuing operations before taxes (98,287 ) 66,491 136,929 (6,049 ) 99,084 (Benefit) taxes on (loss) income from continuing operations (33,234 ) 25,909 23,207 (1,270 ) 14,612 Equity in net income of consolidated subsidiaries 148,784 111,654 219 (260,657 ) — Income from continuing operations 83,731 152,236 113,941 (265,436 ) 84,472 Operating (loss) income from discontinued operations (648 ) — 4 — (644 ) Taxes on (loss) income from discontinued operations 168 — 81 — 249 Loss from discontinued operations (816 ) — (77 ) — (893 ) Net income 82,915 152,236 113,864 (265,436 ) 83,579 Less: Income from continuing operations attributable to noncontrolling interests — — 664 — 664 Net income attributable to common shareholders 82,915 152,236 113,200 (265,436 ) 82,915 Other comprehensive loss attributable to common shareholders (60,215 ) (61,746 ) (75,388 ) 137,134 (60,215 ) Comprehensive income attributable to common shareholders $ 22,700 $ 90,490 $ 37,812 $ (128,302 ) $ 22,700 Six Months Ended June 29, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 552,705 $ 566,088 $ (212,142 ) $ 906,651 Cost of goods sold — 328,396 314,882 (201,874 ) 441,404 Gross profit — 224,309 251,206 (10,268 ) 465,247 Selling, general and administrative expenses 21,803 157,970 107,056 311 287,140 Research and development expenses — 24,895 4,037 — 28,932 Restructuring and impairment charges — 8,491 6,912 — 15,403 (Loss) income from continuing operations before interest and taxes (21,803 ) 32,953 133,201 (10,579 ) 133,772 Interest, net 68,881 (40,647 ) 2,899 — 31,133 (Loss) income from continuing operations before taxes (90,684 ) 73,600 130,302 (10,579 ) 102,639 (Benefit) taxes on (loss) income from continuing operations (31,130 ) 30,753 23,176 (4,259 ) 18,540 Equity in net income of consolidated subsidiaries 142,926 100,358 192 (243,476 ) — Income from continuing operations 83,372 143,205 107,318 (249,796 ) 84,099 Operating loss from discontinued operations (1,619 ) — — — (1,619 ) (Benefit) taxes on loss from discontinued operations (457 ) — 88 — (369 ) Loss from discontinued operations (1,162 ) — (88 ) — (1,250 ) Net income 82,210 143,205 107,230 (249,796 ) 82,849 Less: Income from continuing operations attributable to noncontrolling interests — — 639 — 639 Net income attributable to common shareholders 82,210 143,205 106,591 (249,796 ) 82,210 Other comprehensive income attributable to common shareholders 6,607 4,621 5,728 (10,349 ) 6,607 Comprehensive income attributable to common shareholders $ 88,817 $ 147,826 $ 112,319 $ (260,145 ) $ 88,817 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 26,063 $ 298 $ 298,649 $ — $ 325,010 Accounts receivable, net 2,521 2,785 277,127 3,938 286,371 Accounts receivable from consolidated subsidiaries 13,805 2,230,679 280,218 (2,524,702 ) — Inventories, net — 207,099 168,973 (28,977 ) 347,095 Prepaid expenses and other current assets 12,261 4,897 13,992 3,509 34,659 Prepaid taxes 27,334 — 18,674 — 46,008 Deferred tax assets 30,683 16,408 9,203 — 56,294 Assets held for sale 2,901 — 4,171 — 7,072 Total current assets 115,568 2,462,166 1,071,007 (2,546,232 ) 1,102,509 Property, plant and equipment, net 3,249 173,196 139,091 — 315,536 Goodwill — 704,858 613,016 — 1,317,874 Intangibles assets, net — 727,859 457,658 — 1,185,517 Investments in affiliates 5,565,400 1,403,623 20,984 (6,989,606 ) 401 Deferred tax assets 51,481 — 3,984 (54,331 ) 1,134 Notes receivable and other amounts due from consolidated subsidiaries 1,187,753 1,572,844 — (2,760,597 ) — Other assets 27,216 7,287 26,688 — 61,191 Total assets $ 6,950,667 $ 7,051,833 $ 2,332,428 $ (12,350,766 ) $ 3,984,162 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 370,091 $ — $ 45,900 $ — $ 415,991 Accounts payable 2,369 34,416 37,579 — 74,364 Accounts payable to consolidated subsidiaries 2,284,828 197,490 42,384 (2,524,702 ) — Accrued expenses 16,231 20,341 29,271 — 65,843 Current portion of contingent consideration — 5,802 — — 5,802 Payroll and benefit-related liabilities 20,696 16,054 32,814 — 69,564 Accrued interest 7,971 — 20 — 7,991 Income taxes payable — — 12,836 (1,136 ) 11,700 Other current liabilities 1,851 3,225 5,555 — 10,631 Total current liabilities 2,704,037 277,328 206,359 (2,525,838 ) 661,886 Long-term borrowings 696,000 — — — 696,000 Deferred tax liabilities — 444,282 43,305 (54,330 ) 433,257 Pension and other postretirement benefit liabilities 106,789 34,917 19,330 — 161,036 Noncurrent liability for uncertain tax positions 12,099 15,694 22,754 — 50,547 Notes payable and other amounts due from consolidated subsidiaries 1,492,235 1,087,952 180,410 (2,760,597 ) — Other liabilities 21,728 26,717 12,984 — 61,429 Total liabilities 5,032,888 1,886,890 485,142 (5,340,765 ) 2,064,155 Total common shareholders' equity 1,917,779 5,164,943 1,845,058 (7,010,001 ) 1,917,779 Noncontrolling interest — — 2,228 — 2,228 Total equity 1,917,779 5,164,943 1,847,286 (7,010,001 ) 1,920,007 Total liabilities and equity $ 6,950,667 $ 7,051,833 $ 2,332,428 $ (12,350,766 ) $ 3,984,162 December 31, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 27,996 $ — $ 275,240 $ — $ 303,236 Accounts receivable, net 2,346 2,422 265,081 3,855 273,704 Accounts receivable from consolidated subsidiaries 35,996 2,303,284 272,810 (2,612,090 ) — Inventories, net — 204,335 154,544 (23,286 ) 335,593 Prepaid expenses and other current assets 14,301 4,786 13,102 3,508 35,697 Prepaid taxes 23,493 — 16,763 — 40,256 Deferred tax assets 30,248 17,387 9,666 — 57,301 Assets held for sale 2,901 — 4,521 — 7,422 Total current assets 137,281 2,532,214 1,011,727 (2,628,013 ) 1,053,209 Property, plant and equipment, net 3,489 170,054 143,892 — 317,435 Goodwill — 703,663 619,890 — 1,323,553 Intangibles assets, net — 743,222 473,498 — 1,216,720 Investments in affiliates 5,680,328 1,359,661 21,253 (7,060,092 ) 1,150 Deferred tax assets 52,244 — 5,535 (56,601 ) 1,178 Notes receivable and other amounts due from consolidated subsidiaries 1,009,686 1,489,994 — (2,499,680 ) — Other assets 27,999 6,801 29,210 — 64,010 Total assets $ 6,911,027 $ 7,005,609 $ 2,305,005 $ (12,244,386 ) $ 3,977,255 LIABILITIES AND EQUITY Current liabilities Notes payable $ 363,701 $ — $ 4,700 $ — $ 368,401 Accounts payable 1,449 32,692 29,959 — 64,100 Accounts payable to consolidated subsidiaries 2,259,891 188,908 163,291 (2,612,090 ) — Accrued expenses 17,149 21,479 33,755 — 72,383 Current portion of contingent consideration — 11,276 — — 11,276 Payroll and benefit-related liabilities 20,693 27,228 37,521 — 85,442 Accrued interest 9,152 — 17 — 9,169 Income taxes payable — — 13,634 134 13,768 Other current liabilities 5 3,065 7,290 — 10,360 Total current liabilities 2,672,040 284,648 290,167 (2,611,956 ) 634,899 Long-term borrowings 700,000 — — — 700,000 Deferred tax liabilities — 462,274 45,867 (56,600 ) 451,541 Pension and other postretirement benefit liabilities 110,830 35,074 21,337 — 167,241 Noncurrent liability for uncertain tax positions 11,431 15,569 23,884 — 50,884 Notes payable and other amounts due from consolidated subsidiaries 1,483,984 915,163 100,533 (2,499,680 ) — Other liabilities 21,433 24,900 12,658 — 58,991 Total liabilities 4,999,718 1,737,628 494,446 (5,168,236 ) 2,063,556 Total common shareholders' equity 1,911,309 5,267,981 1,808,169 (7,076,150 ) 1,911,309 Noncontrolling interest — — 2,390 — 2,390 Total equity 1,911,309 5,267,981 1,810,559 (7,076,150 ) 1,913,699 Total liabilities and equity $ 6,911,027 $ 7,005,609 $ 2,305,005 $ (12,244,386 ) $ 3,977,255 TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Six Months Ended June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (92,490 ) $ 63,718 $ 140,720 $ (2,360 ) $ 109,588 Cash Flows from Investing Activities of Continuing Operations: Expenditures for property, plant and equipment (108 ) (17,339 ) (13,874 ) — (31,321 ) Payments for businesses and intangibles acquired, net of cash acquired — (4,348 ) (33,211 ) — (37,559 ) Net cash used in investing activities from continuing operations (108 ) (21,687 ) (47,085 ) — (68,880 ) Cash Flows from Financing Activities of Continuing Operations: Proceeds from long-term borrowings 288,100 — — — 288,100 Repayment of long-term borrowings (250,981 ) — — — (250,981 ) Debt extinguishment, issuance and amendment fees (8,746 ) — — — (8,746 ) Net proceeds from share based compensation plans and the related tax impacts 4,843 — — — 4,843 Payments to noncontrolling interest shareholders — — (832 ) — (832 ) Payments for contingent consideration — (3,989 ) — — (3,989 ) Dividends (28,234 ) — — — (28,234 ) Intercompany transactions 86,197 (37,744 ) (48,453 ) — — Intercompany dividends paid — — (2,360 ) 2,360 — Net cash provided by (used in) financing activities from continuing operations 91,179 (41,733 ) (51,645 ) 2,360 161 Cash Flows from Discontinued Operations: Net cash used in operating activities (514 ) — (849 ) — (1,363 ) Net cash used in discontinued operations (514 ) — (849 ) — (1,363 ) Effect of exchange rate changes on cash and cash equivalents — — (17,732 ) — (17,732 ) Net (decrease) increase in cash and cash equivalents (1,933 ) 298 23,409 — 21,774 Cash and cash equivalents at the beginning of the period 27,996 — 275,240 — 303,236 Cash and cash equivalents at the end of the period $ 26,063 $ 298 $ 298,649 $ — $ 325,010 Six Months Ended June 29, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (49,308 ) $ 277,906 $ (105,302 ) $ (3,135 ) $ 120,161 Cash Flows from Investing Activities of Continuing Operations: Expenditures for property, plant and equipment (2,019 ) (14,080 ) (14,751 ) — (30,850 ) Proceeds from sales of assets and investments 1,669 2,470 — — 4,139 Payments for business and intangibles acquired, net of cash acquired — — (28,535 ) — (28,535 ) Investments in affiliates (60 ) — — — (60 ) Net cash used in investing activities from continuing operations (410 ) (11,610 ) (43,286 ) — (55,306 ) Cash Flows from Financing Activities of Continuing Operations: Proceeds from long-term borrowings 250,000 — — — 250,000 Repayments of long-term borrowings (480,000 ) — — — (480,000 ) Debt extinguishment, issuance and amendment fees (3,275 ) — — — (3,275 ) Payments to noncontrolling interest shareholders — — (1,094 ) — (1,094 ) Net proceeds from share based compensation plans and the related tax impacts 2,391 — — — 2,391 Dividends (28,093 ) — — — (28,093 ) Intercompany transactions 298,760 (277,561 ) (21,199 ) — — Intercompany dividends paid — — (3,135 ) 3,135 — Net cash provided by (used in) financing activities from continuing operations 39,783 (277,561 ) (25,428 ) 3,135 (260,071 ) Cash Flows from Discontinued Operations: Net cash used in operating activities (1,531 ) — — — (1,531 ) Net cash used in discontinued operations (1,531 ) — — — (1,531 ) Effect of exchange rate changes on cash and cash equivalents — — 2,145 — 2,145 Net decrease in cash and cash equivalents (11,466 ) (11,265 ) (171,871 ) — (194,602 ) Cash and cash equivalents at the beginning of the period 42,749 14,500 374,735 — 431,984 Cash and cash equivalents at the end of the period $ 31,283 $ 3,235 $ 202,864 $ — $ 237,382

New accounting standards (Polic

New accounting standards (Policies)	6 Months Ended
	Jun. 28, 2015
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New accounting standards	New accounting standards In May 2014, the Financial Accounting Standards Board ("FASB"), in a joint effort with the International Accounting Standards Board ("IASB"), issued new accounting guidance to clarify the principles for recognizing revenue. The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards. The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers. The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. In July 2015, the FASB deferred the effective date of the new guidance. The guidance is effective prospectively for annual periods beginning after December 15, 2017 and interim periods within those years; early application is permitted for annual periods beginning after December 15, 2016. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows and financial position. In April 2015, FASB issued guidance for the reporting of debt issuance costs within the balance sheet. Under the new guidance, debt issuance costs are to be presented in the balance sheet as a direct deduction from the associated debt liability, consistent with the presentation of a debt discount. Currently, debt issuance costs are presented as a deferred charge (i.e., an asset) on the balance sheet. In addition to providing uniform treatment for debt issuance costs and debt discounts, the guidance is consistent with other FASB guidance, which states that debt issuance costs are similar to debt discounts because they reduce the proceeds of borrowing (thereby increasing the effective interest rate) and cannot be an asset because they provide no future economic benefit. The new guidance is effective for fiscal years beginning after December 15, 2015 with early adoption permitted, and is required to be applied on a retrospective basis. The Company does not believe that the adoption of this guidance will have a material impact on the Company’s financial position. From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed above, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions Acquisitions (Tabl

Acquisitions Acquisitions (Tables)	6 Months Ended
	Jun. 28, 2015
Business Combinations [Abstract]
Acquisitions	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the 2015 acquisitions: (Dollars in thousands) Assets Current assets $ 10,364 Property, plant and equipment 2,475 Intangible assets: Intellectual property 4,067 Non-compete agreements 1,916 Customer list 8,302 Goodwill 18,928 Other assets 45 Total assets acquired 46,097 Less: Current liabilities 3,048 Deferred tax liabilities 2,477 Other liabilities 138 Liabilities assumed 5,663 Net assets acquired $ 40,434

Restructuring and other impairm

Restructuring and other impairment charges (Tables)	6 Months Ended
	Jun. 28, 2015
Restructuring and Related Activities [Abstract]
Summary of Current Cost Estimates by Major Type of Cost Associated with 2014 Manufacturing Footprint Realignment Plan	The following table provides a summary of the Company's current cost estimates by major type of expense associated with the 2014 Manufacturing Footprint Realignment Plan: Type of expense Total estimated amount expected to be incurred Termination benefits $11 million to $13 million Facility closure and other exit costs $2 million to $3 million Accelerated depreciation charges $10 million to $11 million Other $14 million to $17 million $37 million to $44 million
Restructuring and Other Impairment Charges	The restructuring and impairment charges recognized for the three and six months ended June 28, 2015 and June 29, 2014 consisted of the following: Three Months Ended June 28, 2015 (in thousands) Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total 2015 Restructuring programs $ 9 $ 63 $ 24 $ 46 $ 142 2014 Manufacturing footprint realignment plan 75 204 228 — 507 2014 European restructuring plan — — — 18 18 LMA restructuring program — — 9 — 9 2013 Restructuring programs (96 ) — — — (96 ) Total restructuring and impairment charges $ (12 ) $ 267 $ 261 $ 64 $ 580 Three Months Ended June 29, 2014 (in thousands) Termination Benefits Facility Contract Termination Costs Other Exit Costs Total 2014 Manufacturing footprint alignment $ 8,577 $ — $ — $ — $ 8,577 2014 European restructuring plan (566 ) — 305 49 (212 ) 2014 Restructuring charges 476 — 1,174 131 1,781 LMA restructuring program (29 ) (154 ) (2,759 ) — (2,942 ) 2013 Restructuring charges 317 — 57 22 396 2012 Restructuring charges (9 ) 34 — — 25 2011 Restructuring plan — (2 ) — — (2 ) Total restructuring and impairment charges $ 8,766 $ (122 ) $ (1,223 ) $ 202 $ 7,623 Six Months Ended June 28, 2015 (in thousands) Termination Benefits Facility Contract Termination Costs Other Exit Costs Total 2015 Restructuring programs $ 3,559 $ 129 $ 645 $ 47 $ 4,380 2014 Manufacturing footprint realignment plan 212 230 228 — 670 2014 European restructuring plan 9 — — 34 43 Other 2014 restructuring programs — — 49 — 49 LMA restructuring program — — (21 ) 1 (20 ) 2013 Restructuring programs (94 ) — — — (94 ) Total restructuring and impairment charges $ 3,686 $ 359 $ 901 $ 82 $ 5,028 Six Months Ended June 29, 2014 (in thousands) Termination Benefits Facility Closure Costs Contract Termination Costs Other Exit Costs Total 2014 Manufacturing footprint alignment $ 8,577 $ — $ — $ — $ 8,577 2014 European restructuring plan 7,752 — 305 49 8,106 2014 Restructuring charges 476 — 1,174 131 1,781 LMA restructuring program (29 ) (112 ) (3,231 ) — (3,372 ) 2013 Restructuring charges 485 — 57 22 564 2012 Restructuring charges (619 ) 354 — — (265 ) 2011 Restructuring plan — 12 — — 12 Total restructuring and impairment charges $ 16,642 $ 254 $ (1,695 ) $ 202 $ 15,403 Restructuring and impairment charges by reportable operating segment for the three and six months ended June 28, 2015 and June 29, 2014 are set forth in the following table: Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Restructuring and impairment charges Vascular North America $ 520 $ 6,811 $ 2,783 $ 6,886 Anesthesia North America (2 ) 1,151 534 1,178 Surgical North America — — 246 — EMEA (43 ) (1,575 ) (75 ) 6,315 Asia 1 519 1 597 All other 104 717 1,539 427 Total restructuring and impairment charges $ 580 $ 7,623 $ 5,028 $ 15,403

Inventories, net (Tables)

Inventories, net (Tables)	6 Months Ended
	Jun. 28, 2015
Inventory Disclosure [Abstract]
Inventories, net	Inventories as of June 28, 2015 and December 31, 2014 consisted of the following: June 28, 2015 December 31, 2014 (Dollars in thousands) Raw materials $ 74,387 $ 68,191 Work-in-process 60,122 58,526 Finished goods 249,044 242,750 383,553 369,467 Less: inventory reserve (36,458 ) (33,874 ) Inventories, net $ 347,095 $ 335,593

Goodwill and other intangible28

Goodwill and other intangible assets, net (Tables)	6 Months Ended
	Jun. 28, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill, by Reporting Segment	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the six months ended June 28, 2015 : Vascular North America Anesthesia North America Surgical North America EMEA Asia OEM All Other Total (Dollars in thousands) Balance as of December 31, 2014 Goodwill $ 564,177 $ 214,429 $ 250,912 $ 339,029 $ 144,712 $ — $ 142,422 $ 1,655,681 Accumulated impairment losses (219,527 ) (84,531 ) — — — — (28,070 ) (332,128 ) 344,650 129,898 250,912 339,029 144,712 — 114,352 1,323,553 Goodwill related to acquisitions — 12,473 — 1,149 4,112 1,194 — 18,928 Translation adjustment 88 (351 ) — (20,550 ) (2,636 ) — (1,158 ) (24,607 ) Balance at June 28, 2015 Goodwill 564,265 226,551 250,912 319,628 146,188 1,194 141,264 1,650,002 Accumulated impairment losses (219,527 ) (84,531 ) — — — — (28,070 ) (332,128 ) $ 344,738 $ 142,020 $ 250,912 $ 319,628 $ 146,188 $ 1,194 $ 113,194 $ 1,317,874
Components of Intangible Assets	The following table provides information as of June 28, 2015 and December 31, 2014 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net: Gross Carrying Amount Accumulated Amortization June 28, 2015 December 31, 2014 June 28, 2015 December 31, 2014 (Dollars in thousands) Customer relationships $ 625,603 $ 624,574 $ (203,458 ) $ (192,876 ) In-process research and development 41,000 68,694 — — Intellectual property 495,076 467,068 (159,643 ) (146,131 ) Distribution rights 15,660 16,101 (13,969 ) (14,243 ) Trade names 388,322 396,269 (4,990 ) (2,764 ) Non-compete agreements 2,253 337 (337 ) (309 ) $ 1,567,914 $ 1,573,043 $ (382,397 ) $ (356,323 )
Estimated Annual Amortization Expense	stimated annual amortization expense for the remainder of 2015 and the next five succeeding years is as follows (dollars in thousands): 2015 $ 29,200 2016 62,800 2017 62,300 2018 62,100 2019 61,900 2020 61,700

Borrowings (Tables)

Borrowings (Tables)	6 Months Ended
	Jun. 28, 2015
Debt Disclosure [Abstract]
Components of Long-Term Debt	The Company's borrowings at June 28, 2015 and December 31, 2014 are as follows: June 28, 2015 December 31, 2014 (Dollars in thousands) Senior Credit Facility: Revolving credit facility, at a rate of 1.94% at June 28, 2015, due 2018 $ 446,000 $ 200,000 3.875% Convertible Senior Subordinated Notes due 2017 399,817 399,898 6.875% Senior Subordinated Notes due 2019 — 250,000 5.25% Senior Notes due 2024 250,000 250,000 Securitization program, at a rate of 0.94% at June 28, 2015 45,900 4,700 1,141,717 1,104,598 Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017 (29,726 ) (36,197 ) 1,111,991 1,068,401 Current borrowings (415,991 ) (368,401 ) Long-term borrowings $ 696,000 $ 700,000
Fair Value of Long-Term Debt	The following table provides the fair value of the Company’s debt as of June 28, 2015 and December 31, 2014, categorized by the level of inputs within the fair value hierarchy used to measure fair value (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2014 for further information): June 28, 2015 December 31, 2014 (Dollars in thousands) Level 1 $ 878,638 $ 1,024,806 Level 2 735,924 455,222 Total $ 1,614,562 $ 1,480,028

Financial instruments (Tables)

Financial instruments (Tables)	6 Months Ended
	Jun. 28, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair Values of Derivative Instruments Designated as Hedging Instruments	The following table presents the location and fair value of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of June 28, 2015 and December 31, 2014 : June 28, 2015 December 31, 2014 Fair Value Fair Value (Dollars in thousands) Asset derivatives: Foreign currency forward contracts: Prepaid expenses and other current assets $ 419 $ — Total asset derivatives $ 419 $ — Liability derivatives: Foreign currency forward contracts: Other current liabilities $ 1,808 $ — Total liability derivatives $ 1,808 $ —
After Tax Gain/(Loss) Recognized in OCI	The following table provides information as to the gains attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (loss) (“OCI”) for the three and six months ended June 28, 2015 and June 29, 2014 : After Tax Gain (Loss) Recognized in OCI Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Foreign currency forward contracts $ (803 ) $ 73 $ (759 ) $ 143 Total $ (803 ) $ 73 $ (759 ) $ 143
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	June 28, 2015 December 31, 2014 (Dollars in thousands) Current and long-term accounts receivable (net of allowances of $7.7 million and $8.1 million at June 28, 2015 and December 31, 2014, respectively) in Greece, Italy, Spain and Portugal (1) $ 76,384 $ 76,190 Percentage of total net current and long-term accounts receivable - Greece, Italy, Spain and Portugal 26.5 % 27.3 % (1) The long-term portion of accounts receivable, net from customers in Greece, Italy, Spain and Portugal at June 28, 2015 and December 31, 2014 was $9.1 million and $11.3 million , respectively, and is reported on the condensed consolidated balance sheet in other assets.

Fair value measurement (Tables)

Fair value measurement (Tables)	6 Months Ended
	Jun. 28, 2015
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of June 28, 2015 and December 31, 2014 : Total carrying Quoted prices in active markets (Level 1) Significant other Significant (Dollars in thousands) Investments in marketable securities $ 6,960 $ 6,960 $ — $ — Derivative assets 419 — 419 — Derivative liabilities 1,808 — 1,808 — Contingent consideration liabilities 27,150 — — 27,150 Total carrying Quoted prices in active markets (Level 1) Significant other Significant (Dollars in thousands) Investments in marketable securities $ 6,863 $ 6,863 $ — $ — Contingent consideration liabilities 33,433 — — 33,433
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	The following table provides information regarding changes, during the six months ended June 28, 2015, in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions: Contingent consideration 2015 (Dollars in thousands) Balance - December 31, 2014 $ 33,433 Payment (4,000 ) Revaluations (2,283 ) Balance - June 28, 2015 $ 27,150
Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of June 28, 2015 : Valuation Technique Unobservable Input Range (Weighted Average) Contingent consideration Discounted cash flow Discount rate 1.6% - 10% (7.7%) Probability of payment 0% - 100% (57.3%)

Changes in shareholders' equi32

Changes in shareholders' equity (Tables)	6 Months Ended
	Jun. 28, 2015
Equity [Abstract]
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	The following table provides a reconciliation of basic to diluted weighted average shares outstanding: Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Shares in thousands) Basic 41,560 41,380 41,514 41,321 Dilutive effect of share-based awards 473 413 470 442 Dilutive effect of 3.875% Convertible Notes and warrants 6,048 4,599 5,704 4,308 Diluted 48,081 46,392 47,688 46,071
Change in Accumulated Other Comprehensive Income (Loss)	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the six months ended June 28, 2015 and June 29, 2014 : Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance as of December 31, 2014 $ — $ (141,744 ) $ (119,151 ) $ (260,895 ) Other comprehensive income (loss) before reclassifications (922 ) 300 (61,893 ) (62,515 ) Amounts reclassified from accumulated other comprehensive (loss) income 163 2,137 — 2,300 Net current-period other comprehensive income (loss) (759 ) 2,437 (61,893 ) (60,215 ) Balance at June 28, 2015 $ (759 ) $ (139,307 ) $ (181,044 ) $ (321,110 ) Cash Flow Hedges Pension and Other Postretirement Benefit Plans Foreign Currency Translation Adjustment Accumulated Other Comprehensive (Loss) Income (Dollars in thousands) Balance at December 31, 2013 $ — $ (97,037 ) $ (13,818 ) $ (110,855 ) Other comprehensive income (loss) before reclassifications 233 (256 ) 5,222 5,199 Amounts reclassified from accumulated other comprehensive (loss) income (90 ) 1,498 — 1,408 Net current-period other comprehensive income 143 1,242 5,222 6,607 Balance at June 29, 2014 $ 143 $ (95,795 ) $ (8,596 ) $ (104,248 )
Reclassification of Gain/Losses into Income/Expense, Net of Tax	The following table provides information relating to the reclassifications of losses/(gains) in accumulated other comprehensive (loss) income into expense/(income), net of tax, for the three and six months ended June 28, 2015 and June 29, 2014 : Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) (Gains) losses on foreign exchange contracts: Cost of goods sold $ 472 $ (52 ) $ 263 $ (129 ) Total before tax 472 (52 ) 263 (129 ) Tax benefit (110 ) 5 (100 ) 39 Net of tax $ 362 $ (47 ) $ 163 $ (90 ) Amortization of pension and other postretirement benefit items: Actuarial losses (1) $ 1,605 $ 1,103 $ 3,211 $ 2,205 Prior-service costs(1) — (6 ) — (11 ) Total before tax 1,605 1,097 3,211 2,194 Tax expense (564 ) (382 ) (1,074 ) (696 ) Net of tax $ 1,041 $ 715 $ 2,137 $ 1,498 Total reclassifications, net of tax $ 1,403 $ 668 $ 2,300 $ 1,408 (1) These accumulated other comprehensive income (loss) components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui33

Taxes on income from continuing operations (Tables)	6 Months Ended
	Jun. 28, 2015
Income Tax Disclosure [Abstract]
Effective Income Tax Rate	The effective income tax rates for the three and six months ended June 28, 2015 and June 29, 2014 are as follows: Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 Effective income tax rate 10.5% 17.0% 14.7% 18.1%

Pension and other postretirem34

Pension and other postretirement benefits (Tables)	6 Months Ended
	Jun. 28, 2015
Compensation and Retirement Disclosure [Abstract]
Net Benefit Cost of Pension and Postretirement Benefit Plans	Net benefit cost of pension and postretirement benefit plans consisted of the following: Pension Other Postretirement Benefits Pension Other Postretirement Benefits June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Service cost $ 469 $ 447 $ 107 $ 138 $ 940 $ 897 $ 214 $ 276 Interest cost 4,485 4,486 $ 511 596 8,971 8,969 1,023 1,193 Expected return on plan assets (6,427 ) (6,264 ) $ — — (12,852 ) (12,524 ) — — Net amortization and deferral 1,528 1,070 $ 78 27 3,058 2,141 155 53 Net benefit expense (income) $ 55 $ (261 ) $ 696 $ 761 $ 117 $ (517 ) $ 1,392 $ 1,522

Business segment information (T

Business segment information (Tables)	6 Months Ended
	Jun. 28, 2015
Segment Reporting [Abstract]
Segment Results	The following tables present the Company’s segment results for the three and six months ended June 28, 2015 and June 29, 2014 : Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Revenue Vascular North America $ 81,165 $ 77,203 $ 161,931 $ 152,062 Anesthesia North America 45,579 45,730 91,028 88,982 Surgical North America 40,520 37,969 78,579 73,200 EMEA 129,132 154,670 258,414 304,915 Asia 62,042 62,539 110,571 112,141 OEM 37,918 36,610 72,633 69,792 All other 55,689 53,384 108,319 105,559 Consolidated net revenues $ 452,045 $ 468,105 $ 881,475 $ 906,651 Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Operating profit Vascular North America $ 17,055 $ 13,544 $ 32,805 $ 25,709 Anesthesia North America 11,434 8,399 21,394 15,364 Surgical North America 14,315 14,366 26,642 24,914 EMEA 19,343 30,080 45,678 56,961 Asia 18,951 17,096 27,097 29,933 OEM 8,366 8,296 16,409 14,900 All other 6,855 4,693 9,948 10,410 Total segment operating profit (1) 96,319 96,474 179,973 178,191 Unallocated expenses (2) (19,333 ) (21,722 ) (37,379 ) (44,419 ) Income from continuing operations before interest, extinguishment of debt and taxes $ 76,986 $ 74,752 $ 142,594 $ 133,772 (1) Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved. (2) Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and impairment charges. Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Depreciation and amortization Vascular North America $ 9,265 $ 9,061 $ 18,413 $ 17,932 Anesthesia North America 1,552 3,111 3,194 6,355 Surgical North America 2,348 1,666 4,826 4,035 EMEA 8,342 9,673 16,240 18,610 Asia 3,010 2,305 5,408 4,143 OEM 1,704 1,608 3,371 3,064 All other 4,561 4,978 9,180 9,676 Consolidated depreciation and amortization $ 30,782 $ 32,402 $ 60,632 $ 63,815
Schedule of Revenues and Property Plant Equipment by Geographic Region	The following table provides total net revenues for the three months ended June 28, 2015 and June 29, 2014 and total net property, plant and equipment by geographic region as of June 28, 2015 and December 31, 2014 : Three Months Ended Six Months Ended June 28, 2015 June 29, 2014 June 28, 2015 June 29, 2014 (Dollars in thousands) Net revenue (based on selling location) United States $ 238,518 $ 228,349 $ 469,724 $ 444,810 Other Americas 15,122 15,187 28,563 29,959 Europe 143,692 174,193 284,375 342,967 All other 54,713 50,376 98,813 88,915 $ 452,045 $ 468,105 $ 881,475 $ 906,651
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country	June 28, 2015 December 31, 2014 (Dollars in thousands) Net property, plant and equipment United States $ 177,772 $ 174,893 Malaysia 35,594 36,427 Czech Republic 33,612 35,655 All other 68,558 70,460 $ 315,536 $ 317,435

Condensed consolidating guara36

Condensed consolidating guarantor financial information (Tables)	6 Months Ended
	Jun. 28, 2015
Condensed Consolidated Guarantor Financial Information [Abstract]
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (LOSS) Three Months Ended June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 269,703 $ 276,258 $ (93,916 ) $ 452,045 Cost of goods sold — 158,718 152,355 (92,265 ) 218,808 Gross profit — 110,985 123,903 (1,651 ) 233,237 Selling, general and administrative expenses 8,663 82,844 50,964 (243 ) 142,228 Research and development expenses — 4,894 8,549 — 13,443 Restructuring and impairment charges — 591 (11 ) — 580 (Loss) income from continuing operations before interest, extinguishment of debt and taxes (8,663 ) 22,656 64,401 (1,408 ) 76,986 Interest, net 33,358 (18,565 ) 1,260 — 16,053 Loss on extinguishment of debt, net 10,454 — — — 10,454 (Loss) income from continuing operations before taxes (52,475 ) 41,221 63,141 (1,408 ) 50,479 (Benefit) taxes on income from continuing operations (17,941 ) 14,917 8,463 (159 ) 5,280 Equity in net income of consolidated subsidiaries 79,246 51,964 122 (131,332 ) — Income from continuing operations 44,712 78,268 54,800 (132,581 ) 45,199 Operating loss from discontinued operations (145 ) — — — (145 ) Taxes on loss from discontinued operations 4 — 41 — 45 Loss from discontinued operations (149 ) — (41 ) — (190 ) Net income 44,563 78,268 54,759 (132,581 ) 45,009 Less: Income from continuing operations attributable to noncontrolling interests — — 446 — 446 Net income attributable to common shareholders 44,563 78,268 54,313 (132,581 ) 44,563 Other comprehensive income attributable to common shareholders 20,986 45,015 24,340 (69,355 ) 20,986 Comprehensive income attributable to common shareholders $ 65,549 $ 123,283 $ 78,653 $ (201,936 ) $ 65,549 Three Months Ended June 29, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net revenues $ — $ 290,280 $ 317,651 $ (139,826 ) $ 468,105 Cost of goods sold — 176,028 177,009 (129,020 ) 224,017 Gross profit — 114,252 140,642 (10,806 ) 244,088 Selling, general and administrative expenses 11,025 76,575 59,135 108 146,843 Research and development expenses — 12,885 1,985 — 14,870 Restructuring and impairment charges — 8,679 (1,056 ) — 7,623 (Loss) income from continuing operations before interest and taxes (11,025 ) 16,113 80,578 (10,914 ) 74,752 Interest, net 35,155 (20,740 ) 1,501 — 15,916 (Loss) income from continuing operations before taxes (46,180 ) 36,853 79,077 (10,914 ) 58,836 (Benefit) taxes on income from continuing operations (15,710 ) 13,535 14,344 (2,163 ) 10,006 Equity in net income of consolidated subsidiaries 78,802 57,250 98 (136,150 ) — Income from continuing operations 48,332 80,568 64,831 (144,901 ) 48,830 Operating loss from discontinued operations (1,594 ) — — — (1,594 ) (Benefit) taxes on loss from discontinued operations (514 ) — 45 — (469 ) Loss from discontinued operations (1,080 ) — (45 ) — (1,125 ) Net income 47,252 80,568 64,786 (144,901 ) 47,705 Less: Income from continuing operations attributable to noncontrolling interests — — 453 — 453 Net income attributable to common shareholders 47,252 80,568 64,333 (144,901 ) 47,252 Other comprehensive income (loss) attributable to common shareholders 1,862 (2,607 ) (5,984 ) 8,591 1,862 Comprehensive income attributable to common shareholders $ 49,114 $ 77,961 $ 58,349 $ (136,310 ) $ 49,114
Condensed Consolidating Balance Sheets	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING BALANCE SHEETS June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 26,063 $ 298 $ 298,649 $ — $ 325,010 Accounts receivable, net 2,521 2,785 277,127 3,938 286,371 Accounts receivable from consolidated subsidiaries 13,805 2,230,679 280,218 (2,524,702 ) — Inventories, net — 207,099 168,973 (28,977 ) 347,095 Prepaid expenses and other current assets 12,261 4,897 13,992 3,509 34,659 Prepaid taxes 27,334 — 18,674 — 46,008 Deferred tax assets 30,683 16,408 9,203 — 56,294 Assets held for sale 2,901 — 4,171 — 7,072 Total current assets 115,568 2,462,166 1,071,007 (2,546,232 ) 1,102,509 Property, plant and equipment, net 3,249 173,196 139,091 — 315,536 Goodwill — 704,858 613,016 — 1,317,874 Intangibles assets, net — 727,859 457,658 — 1,185,517 Investments in affiliates 5,565,400 1,403,623 20,984 (6,989,606 ) 401 Deferred tax assets 51,481 — 3,984 (54,331 ) 1,134 Notes receivable and other amounts due from consolidated subsidiaries 1,187,753 1,572,844 — (2,760,597 ) — Other assets 27,216 7,287 26,688 — 61,191 Total assets $ 6,950,667 $ 7,051,833 $ 2,332,428 $ (12,350,766 ) $ 3,984,162 LIABILITIES AND EQUITY Current liabilities Current borrowings $ 370,091 $ — $ 45,900 $ — $ 415,991 Accounts payable 2,369 34,416 37,579 — 74,364 Accounts payable to consolidated subsidiaries 2,284,828 197,490 42,384 (2,524,702 ) — Accrued expenses 16,231 20,341 29,271 — 65,843 Current portion of contingent consideration — 5,802 — — 5,802 Payroll and benefit-related liabilities 20,696 16,054 32,814 — 69,564 Accrued interest 7,971 — 20 — 7,991 Income taxes payable — — 12,836 (1,136 ) 11,700 Other current liabilities 1,851 3,225 5,555 — 10,631 Total current liabilities 2,704,037 277,328 206,359 (2,525,838 ) 661,886 Long-term borrowings 696,000 — — — 696,000 Deferred tax liabilities — 444,282 43,305 (54,330 ) 433,257 Pension and other postretirement benefit liabilities 106,789 34,917 19,330 — 161,036 Noncurrent liability for uncertain tax positions 12,099 15,694 22,754 — 50,547 Notes payable and other amounts due from consolidated subsidiaries 1,492,235 1,087,952 180,410 (2,760,597 ) — Other liabilities 21,728 26,717 12,984 — 61,429 Total liabilities 5,032,888 1,886,890 485,142 (5,340,765 ) 2,064,155 Total common shareholders' equity 1,917,779 5,164,943 1,845,058 (7,010,001 ) 1,917,779 Noncontrolling interest — — 2,228 — 2,228 Total equity 1,917,779 5,164,943 1,847,286 (7,010,001 ) 1,920,007 Total liabilities and equity $ 6,950,667 $ 7,051,833 $ 2,332,428 $ (12,350,766 ) $ 3,984,162 December 31, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) ASSETS Current assets Cash and cash equivalents $ 27,996 $ — $ 275,240 $ — $ 303,236 Accounts receivable, net 2,346 2,422 265,081 3,855 273,704 Accounts receivable from consolidated subsidiaries 35,996 2,303,284 272,810 (2,612,090 ) — Inventories, net — 204,335 154,544 (23,286 ) 335,593 Prepaid expenses and other current assets 14,301 4,786 13,102 3,508 35,697 Prepaid taxes 23,493 — 16,763 — 40,256 Deferred tax assets 30,248 17,387 9,666 — 57,301 Assets held for sale 2,901 — 4,521 — 7,422 Total current assets 137,281 2,532,214 1,011,727 (2,628,013 ) 1,053,209 Property, plant and equipment, net 3,489 170,054 143,892 — 317,435 Goodwill — 703,663 619,890 — 1,323,553 Intangibles assets, net — 743,222 473,498 — 1,216,720 Investments in affiliates 5,680,328 1,359,661 21,253 (7,060,092 ) 1,150 Deferred tax assets 52,244 — 5,535 (56,601 ) 1,178 Notes receivable and other amounts due from consolidated subsidiaries 1,009,686 1,489,994 — (2,499,680 ) — Other assets 27,999 6,801 29,210 — 64,010 Total assets $ 6,911,027 $ 7,005,609 $ 2,305,005 $ (12,244,386 ) $ 3,977,255 LIABILITIES AND EQUITY Current liabilities Notes payable $ 363,701 $ — $ 4,700 $ — $ 368,401 Accounts payable 1,449 32,692 29,959 — 64,100 Accounts payable to consolidated subsidiaries 2,259,891 188,908 163,291 (2,612,090 ) — Accrued expenses 17,149 21,479 33,755 — 72,383 Current portion of contingent consideration — 11,276 — — 11,276 Payroll and benefit-related liabilities 20,693 27,228 37,521 — 85,442 Accrued interest 9,152 — 17 — 9,169 Income taxes payable — — 13,634 134 13,768 Other current liabilities 5 3,065 7,290 — 10,360 Total current liabilities 2,672,040 284,648 290,167 (2,611,956 ) 634,899 Long-term borrowings 700,000 — — — 700,000 Deferred tax liabilities — 462,274 45,867 (56,600 ) 451,541 Pension and other postretirement benefit liabilities 110,830 35,074 21,337 — 167,241 Noncurrent liability for uncertain tax positions 11,431 15,569 23,884 — 50,884 Notes payable and other amounts due from consolidated subsidiaries 1,483,984 915,163 100,533 (2,499,680 ) — Other liabilities 21,433 24,900 12,658 — 58,991 Total liabilities 4,999,718 1,737,628 494,446 (5,168,236 ) 2,063,556 Total common shareholders' equity 1,911,309 5,267,981 1,808,169 (7,076,150 ) 1,911,309 Noncontrolling interest — — 2,390 — 2,390 Total equity 1,911,309 5,267,981 1,810,559 (7,076,150 ) 1,913,699 Total liabilities and equity $ 6,911,027 $ 7,005,609 $ 2,305,005 $ (12,244,386 ) $ 3,977,255
Condensed Consolidating Statements of Cash Flows	TELEFLEX INCORPORATED AND SUBSIDIARIES CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS Six Months Ended June 28, 2015 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (92,490 ) $ 63,718 $ 140,720 $ (2,360 ) $ 109,588 Cash Flows from Investing Activities of Continuing Operations: Expenditures for property, plant and equipment (108 ) (17,339 ) (13,874 ) — (31,321 ) Payments for businesses and intangibles acquired, net of cash acquired — (4,348 ) (33,211 ) — (37,559 ) Net cash used in investing activities from continuing operations (108 ) (21,687 ) (47,085 ) — (68,880 ) Cash Flows from Financing Activities of Continuing Operations: Proceeds from long-term borrowings 288,100 — — — 288,100 Repayment of long-term borrowings (250,981 ) — — — (250,981 ) Debt extinguishment, issuance and amendment fees (8,746 ) — — — (8,746 ) Net proceeds from share based compensation plans and the related tax impacts 4,843 — — — 4,843 Payments to noncontrolling interest shareholders — — (832 ) — (832 ) Payments for contingent consideration — (3,989 ) — — (3,989 ) Dividends (28,234 ) — — — (28,234 ) Intercompany transactions 86,197 (37,744 ) (48,453 ) — — Intercompany dividends paid — — (2,360 ) 2,360 — Net cash provided by (used in) financing activities from continuing operations 91,179 (41,733 ) (51,645 ) 2,360 161 Cash Flows from Discontinued Operations: Net cash used in operating activities (514 ) — (849 ) — (1,363 ) Net cash used in discontinued operations (514 ) — (849 ) — (1,363 ) Effect of exchange rate changes on cash and cash equivalents — — (17,732 ) — (17,732 ) Net (decrease) increase in cash and cash equivalents (1,933 ) 298 23,409 — 21,774 Cash and cash equivalents at the beginning of the period 27,996 — 275,240 — 303,236 Cash and cash equivalents at the end of the period $ 26,063 $ 298 $ 298,649 $ — $ 325,010 Six Months Ended June 29, 2014 Parent Guarantor Non-Guarantor Eliminations Condensed (Dollars in thousands) Net cash (used in) provided by operating activities from continuing operations $ (49,308 ) $ 277,906 $ (105,302 ) $ (3,135 ) $ 120,161 Cash Flows from Investing Activities of Continuing Operations: Expenditures for property, plant and equipment (2,019 ) (14,080 ) (14,751 ) — (30,850 ) Proceeds from sales of assets and investments 1,669 2,470 — — 4,139 Payments for business and intangibles acquired, net of cash acquired — — (28,535 ) — (28,535 ) Investments in affiliates (60 ) — — — (60 ) Net cash used in investing activities from continuing operations (410 ) (11,610 ) (43,286 ) — (55,306 ) Cash Flows from Financing Activities of Continuing Operations: Proceeds from long-term borrowings 250,000 — — — 250,000 Repayments of long-term borrowings (480,000 ) — — — (480,000 ) Debt extinguishment, issuance and amendment fees (3,275 ) — — — (3,275 ) Payments to noncontrolling interest shareholders — — (1,094 ) — (1,094 ) Net proceeds from share based compensation plans and the related tax impacts 2,391 — — — 2,391 Dividends (28,093 ) — — — (28,093 ) Intercompany transactions 298,760 (277,561 ) (21,199 ) — — Intercompany dividends paid — — (3,135 ) 3,135 — Net cash provided by (used in) financing activities from continuing operations 39,783 (277,561 ) (25,428 ) 3,135 (260,071 ) Cash Flows from Discontinued Operations: Net cash used in operating activities (1,531 ) — — — (1,531 ) Net cash used in discontinued operations (1,531 ) — — — (1,531 ) Effect of exchange rate changes on cash and cash equivalents — — 2,145 — 2,145 Net decrease in cash and cash equivalents (11,466 ) (11,265 ) (171,871 ) — (194,602 ) Cash and cash equivalents at the beginning of the period 42,749 14,500 374,735 — 431,984 Cash and cash equivalents at the end of the period $ 31,283 $ 3,235 $ 202,864 $ — $ 237,382

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014	Apr. 08, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Total fair value of consideration						$ 66,300
Initial payment			$ 37,800
Consideration transferred			1,800
Transaction expenses			700
Net revenues	$ 452,045	$ 468,105	881,475	$ 906,651
Income (loss) from continuing operations before taxes	50,479	$ 58,836	99,084	$ 102,639
Truphatek
Business Acquisition [Line Items]
Noncontrolling interest					6.00%
Equity interest held			1,200
Working capital adjustment related to acquisition			400
Fair value of minority interest gain			1,000
Business Combinations 2015
Business Acquisition [Line Items]
Total fair value of consideration	40,434		40,434
Net revenues	1,800		2,600
Income (loss) from continuing operations before taxes	$ 300		$ 900
Intellectual Property | Minimum
Business Acquisition [Line Items]
Intangible asset useful life			15 years
Intellectual Property | Maximum
Business Acquisition [Line Items]
Intangible asset useful life			20 years
Customer Lists | Minimum
Business Acquisition [Line Items]
Intangible asset useful life			10 years
Customer Lists | Maximum
Business Acquisition [Line Items]
Intangible asset useful life			18 years
Non-compete Agreements
Business Acquisition [Line Items]
Intangible asset useful life			5 years

Acquisitions Acquisitions - Ass

Acquisitions Acquisitions - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Assets
Goodwill	$ 1,317,874	$ 1,323,553
Less:
Net assets acquired		$ 66,300
Business Combinations 2015
Assets
Current assets	10,364
Property, plant and equipment	2,475
Goodwill	18,928
Other assets	45
Total assets acquired	46,097
Less:
Current liabilities	3,048
Deferred tax liabilities	2,477
Other liabilities	138
Liabilities assumed	5,663
Net assets acquired	40,434
Business Combinations 2015 | Intellectual Property
Assets
Intangible assets:	4,067
Business Combinations 2015 | Non-compete Agreements
Assets
Intangible assets:	1,916
Business Combinations 2015 | Customer Lists
Assets
Intangible assets:	$ 8,302

Restructuring and impairment 39

Restructuring and impairment charges - additional information (Detail) - USD ($)	3 Months Ended		6 Months Ended		13 Months Ended	14 Months Ended	16 Months Ended	30 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 28, 2015	Jun. 28, 2015	Jun. 28, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 580,000	$ 7,623,000	$ 5,028,000	$ 15,403,000
Impairment charges	0	0	0	0
Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	261,000	(1,223,000)	901,000	(1,695,000)
Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	267,000	(122,000)	359,000	254,000
Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	64,000	202,000	82,000	202,000
2015 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	142,000		4,380,000
Restructuring reserve	3,500,000		3,500,000		$ 3,500,000	$ 3,500,000	$ 3,500,000	$ 3,500,000
2015 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	24,000		645,000
2015 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	63,000		129,000
2015 Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	46,000		47,000
2015 Restructuring Program | Minimum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	6,000,000		6,000,000		6,000,000	6,000,000	6,000,000	6,000,000
2015 Restructuring Program | Maximum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	7,000,000		7,000,000		7,000,000	7,000,000	7,000,000	7,000,000
2014 Manufacturing Footprint Realignment
Restructuring Cost And Reserve [Line Items]
Restructuring expenses	3,600,000		5,900,000			10,000,000
Restructuring charges	507,000	8,577,000	670,000	8,577,000
Restructuring reserve	7,500,000		7,500,000		7,500,000	7,500,000	7,500,000	7,500,000
2014 Manufacturing Footprint Realignment | Accelerated Depreciation And Other Costs
Restructuring Cost And Reserve [Line Items]
Restructuring expenses						10,100,000
Restructuring and Related Cost, Accelerated Depreciation	3,100,000		5,200,000
2014 Manufacturing Footprint Realignment | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	228,000	0	228,000	0
2014 Manufacturing Footprint Realignment | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	204,000	0	230,000	0
2014 Manufacturing Footprint Realignment | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	0	0
2014 Manufacturing Footprint Realignment | Minimum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	37,000,000		37,000,000		37,000,000	37,000,000	37,000,000	37,000,000
Restructuring costs expected cash payment	26,000,000		26,000,000		26,000,000	26,000,000	26,000,000	26,000,000
2014 Manufacturing Footprint Realignment | Minimum | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	11,000,000		11,000,000		11,000,000	11,000,000	11,000,000	11,000,000
2014 Manufacturing Footprint Realignment | Minimum | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	2,000,000		2,000,000		2,000,000	2,000,000	2,000,000	2,000,000
2014 Manufacturing Footprint Realignment | Minimum | Accelerated Depreciation Charges
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	10,000,000		10,000,000		10,000,000	10,000,000	10,000,000	10,000,000
2014 Manufacturing Footprint Realignment | Minimum | Other
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	14,000,000		14,000,000		14,000,000	14,000,000	14,000,000	14,000,000
2014 Manufacturing Footprint Realignment | Maximum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	44,000,000		44,000,000		44,000,000	44,000,000	44,000,000	44,000,000
Restructuring costs expected cash payment	31,000,000		31,000,000		31,000,000	31,000,000	31,000,000	31,000,000
2014 Manufacturing Footprint Realignment | Maximum | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	13,000,000		13,000,000		13,000,000	13,000,000	13,000,000	13,000,000
2014 Manufacturing Footprint Realignment | Maximum | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	3,000,000		3,000,000		3,000,000	3,000,000	3,000,000	3,000,000
2014 Manufacturing Footprint Realignment | Maximum | Accelerated Depreciation Charges
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	11,000,000		11,000,000		11,000,000	11,000,000	11,000,000	11,000,000
2014 Manufacturing Footprint Realignment | Maximum | Other
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	17,000,000		17,000,000		17,000,000	17,000,000	17,000,000	17,000,000
2014 European Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring expenses							7,900,000
Restructuring charges	18,000	(212,000)	43,000	8,106,000
Restructuring reserve	400,000		400,000		400,000	400,000	400,000	400,000
2014 European Restructuring Plan | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	305,000	0	305,000
2014 European Restructuring Plan | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	0	0
2014 European Restructuring Plan | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	18,000	49,000	34,000	49,000
2014 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges		1,781,000	49,000	1,781,000	3,600,000
Restructuring reserve	600,000		600,000		600,000	600,000	600,000	600,000
2014 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		1,174,000	49,000	1,174,000
2014 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0	0	0
2014 Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges		131,000	0	131,000
2014 Restructuring Program | Maximum
Restructuring Cost And Reserve [Line Items]
Expected restructuring charges	4,000,000		4,000,000		4,000,000	4,000,000	4,000,000	4,000,000
LMA Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	9,000	(2,942,000)	(20,000)	(3,372,000)				11,300,000
LMA Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	9,000	(2,759,000)	(21,000)	(3,231,000)
LMA Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	(154,000)	0	(112,000)
LMA Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	1,000	0
2013 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	(96,000)	396,000	(94,000)	564,000				11,000,000
2013 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	57,000	0	57,000
2013 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	0	0
2013 Restructuring Program | Other
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	$ 22,000	0	$ 22,000
2012 Restructuring Charges
Restructuring Cost And Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	6,300,000		6,300,000		6,300,000	6,300,000	6,300,000	6,300,000
Restructuring reserve	$ 500,000		$ 500,000		$ 500,000	$ 500,000	$ 500,000	$ 500,000

Restructuring and impairment 40

Restructuring and impairment charges (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		13 Months Ended	30 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 28, 2015
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 580	$ 7,623	$ 5,028	$ 15,403
Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	(12)	8,766	3,686	16,642
Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	267	(122)	359	254
Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	261	(1,223)	901	(1,695)
Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	64	202	82	202
2015 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	142		4,380
2015 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	9		3,559
2015 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	63		129
2015 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	24		645
2015 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	46		47
2014 Manufacturing Footprint Realignment
Restructuring Cost And Reserve [Line Items]
Restructuring charges	507	8,577	670	8,577
2014 Manufacturing Footprint Realignment | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	75	8,577	212	8,577
2014 Manufacturing Footprint Realignment | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	204	0	230	0
2014 Manufacturing Footprint Realignment | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	228	0	228	0
2014 Manufacturing Footprint Realignment | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	0	0
2014 European Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges	18	(212)	43	8,106
2014 European Restructuring Plan | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	(566)	9	7,752
2014 European Restructuring Plan | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	0	0
2014 European Restructuring Plan | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	305	0	305
2014 European Restructuring Plan | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	18	49	34	49
2014 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges		1,781	49	1,781	$ 3,600
2014 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges		476	0	476
2014 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0	0	0
2014 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		1,174	49	1,174
2014 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		131	0	131
LMA Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	9	(2,942)	(20)	(3,372)		$ 11,300
LMA Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	(29)	0	(29)
LMA Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	(154)	0	(112)
LMA Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	9	(2,759)	(21)	(3,231)
LMA Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	1	0
2013 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges	(96)	396	(94)	564		$ 11,000
2013 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges	(96)	317	(94)	485
2013 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	0	0	0
2013 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	0	57	0	57
2013 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges	$ 0	22	$ 0	22
2012 Restructuring Program
Restructuring Cost And Reserve [Line Items]
Restructuring charges		25		(265)
2012 Restructuring Program | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges		(9)		(619)
2012 Restructuring Program | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		34		354
2012 Restructuring Program | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0		0
2012 Restructuring Program | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0		0
2011 Restructuring Plan
Restructuring Cost And Reserve [Line Items]
Restructuring charges		(2)		12
2011 Restructuring Plan | Termination Benefits
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0		0
2011 Restructuring Plan | Facility Closure Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		(2)		12
2011 Restructuring Plan | Contract Termination Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		0		0
2011 Restructuring Plan | Other Exit Costs
Restructuring Cost And Reserve [Line Items]
Restructuring charges		$ 0		$ 0

Restructuring and impairment 41

Restructuring and impairment charges by segment (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Restructuring and other impairment charges
Restructuring charges	$ 580	$ 7,623	$ 5,028	$ 15,403
Vascular North America
Restructuring and other impairment charges
Restructuring charges	520	6,811	2,783	6,886
Anesthesia North America
Restructuring and other impairment charges
Restructuring charges	(2)	1,151	534	1,178
Surgical North America
Restructuring and other impairment charges
Restructuring charges	0	0	246	0
EMEA
Restructuring and other impairment charges
Restructuring charges	(43)	(1,575)	(75)	6,315
Asia
Restructuring and other impairment charges
Restructuring charges	1	519	1	597
All Other
Restructuring and other impairment charges
Restructuring charges	$ 104	$ 717	$ 1,539	$ 427

Inventories, net (Detail)

Inventories, net (Detail) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 74,387	$ 68,191
Work-in-process	60,122	58,526
Finished goods	249,044	242,750
Inventories, gross	383,553	369,467
Less: inventory reserve	(36,458)	(33,874)
Inventories, net	$ 347,095	$ 335,593

Goodwill and other intangible43

Goodwill and other intangible assets, net Changes in carrying amount of goodwill, by reporting segment (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 28, 2015	Dec. 31, 2014
Goodwill [Roll Forward]
Goodwill	$ 1,655,681
Accumulated impairment losses	(332,128)	$ (332,128)
Goodwill related to acquisitions	18,928
Translation adjustment	(24,607)
Goodwill	1,317,874
Vascular North America
Goodwill [Roll Forward]
Goodwill	564,177
Accumulated impairment losses	(219,527)	(219,527)
Goodwill related to acquisitions	0
Translation adjustment	88
Goodwill	344,738
Anesthesia North America
Goodwill [Roll Forward]
Goodwill	214,429
Accumulated impairment losses	(84,531)	(84,531)
Goodwill related to acquisitions	12,473
Translation adjustment	(351)
Goodwill	142,020
Surgical North America
Goodwill [Roll Forward]
Goodwill	250,912
Accumulated impairment losses	0	0
Goodwill related to acquisitions	0
Translation adjustment	0
Goodwill	250,912
EMEA
Goodwill [Roll Forward]
Goodwill	339,029
Accumulated impairment losses	0	0
Goodwill related to acquisitions	1,149
Translation adjustment	(20,550)
Goodwill	319,628
Asia
Goodwill [Roll Forward]
Goodwill	144,712
Accumulated impairment losses	0	0
Goodwill related to acquisitions	4,112
Translation adjustment	(2,636)
Goodwill	146,188
OEM
Goodwill [Roll Forward]
Goodwill	0
Accumulated impairment losses	0	0
Goodwill related to acquisitions	1,194
Translation adjustment	0
Goodwill	1,194
All Other
Goodwill [Roll Forward]
Goodwill	142,422
Accumulated impairment losses	(28,070)	$ (28,070)
Goodwill related to acquisitions	0
Translation adjustment	(1,158)
Goodwill	$ 113,194

Goodwill and other intangible44

Goodwill and other intangible assets, net Components of intangible assets (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	$ 1,567,914	$ 1,573,043
Accumulated amortization	(382,397)	(356,323)
Customer Relationships
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	625,603	624,574
Accumulated amortization	(203,458)	(192,876)
Intellectual Property
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	495,076	467,068
Accumulated amortization	(159,643)	(146,131)
Distribution Rights
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	15,660	16,101
Accumulated amortization	(13,969)	(14,243)
Trade Names
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	388,322	396,269
Accumulated amortization	(4,990)	(2,764)
Non-compete Agreements
Finite-Lived Intangible Assets [Line Items]
Gross carrying amount	2,253	337
Accumulated amortization	(337)	(309)
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Accumulated amortization	0	0
Indefinite-lived intangible assets	$ 41,000	$ 68,694

Goodwill and other intangible45

Goodwill and other intangible assets, net - additional information (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Amortization expense of intangible assets	$ 15,100	$ 16,100	$ 29,826	$ 32,102
In Process Research and Development
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	41,000		41,000		$ 68,694
In Process Research and Development | Semprus Technology
Finite-Lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	$ 41,000		$ 41,000

Goodwill and other intangible46

Goodwill and other intangible assets, net Annual amortization expense (Details) $ in Thousands	Jun. 28, 2015USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2,015	$ 29,200
2,016	62,800
2,017	62,300
2,018	62,100
2,019	61,900
2,020	$ 61,700

Borrowings Components of long-t

Borrowings Components of long-term debt (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Jun. 01, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Revolving credit facility, at a rate of 1.94% at June 28, 2015, due 2018	$ 446,000		$ 200,000
Total borrowings	1,141,717		1,104,598
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes due 2017	(29,726)		(36,197)
Total long-term debt	1,111,991		1,068,401
Current borrowings	(415,991)		(368,401)
Long-term borrowings	696,000		700,000
3.875% Convertible Senior Subordinated Notes
Debt Instrument [Line Items]
3.875% Convertible Senior Subordinated Notes due 2017	399,817		399,898
6.875% Senior Subordinated Notes due 2019
Debt Instrument [Line Items]
6.875% Senior Subordinated Notes due 2019	0	$ 250,000	250,000
5.25% Senior Subordinated Notes Due 2024
Debt Instrument [Line Items]
5.25% Senior Notes due 2024	250,000		250,000
Securitization Program
Debt Instrument [Line Items]
Securitization program, at a rate of 0.94% at June 28, 2015	$ 45,900		$ 4,700

Borrowings - Additional Informa

Borrowings - Additional Information (Detail) - USD ($)	Jul. 29, 2015	Jun. 01, 2015	May. 21, 2014	Jun. 28, 2015	Jun. 28, 2015	Dec. 31, 2013	Dec. 31, 2014	Jun. 29, 2014
Debt Instrument [Line Items]
Debt instrument, stated interest rate				3.875%	3.875%			3.875%
Proceeds from securitization		$ 12,100,000
Total long-term debt				$ 1,111,991,000	$ 1,111,991,000		$ 1,068,401,000
Line of credit facility interest rate				1.94%
Revolving Credit Facility
Debt Instrument [Line Items]
Proceeds from lines of credit		$ 246,000,000
Revolving Credit Facility | Subsequent Event
Debt Instrument [Line Items]
Repayment of lines of credit	$ 50,000,000
Convertible Senior Subordinated Notes
Debt Instrument [Line Items]
Number of trading period					20 days
Number of consecutive trading period					30 days
Threshold percentage of stock price trigger					130.00%
Number of business period					5 days
Principal amount of convertible notes					$ 1,000
Percentage of product of last reported sale price of common stock					98.00%
Conversion ratio					16.3084
Conversion price, per share				$ 61.32	$ 61.32
3.875% Convertible Senior Subordinated Notes
Debt Instrument [Line Items]
Debt instrument, stated interest rate				3.875%	3.875%		3.875%
Debt instrument maturity date					Aug. 1, 2017
6.875% Senior Subordinated Notes due 2019
Debt Instrument [Line Items]
Debt instrument, stated interest rate		6.875%		6.875%	6.875%		6.875%
6.875% senior subordinated notes due 2019		$ 250,000,000		$ 0	$ 0		$ 250,000,000
Prepayment of debt		$ 8,600,000
Write-off of unamortized debt issuance costs				$ 1,900,000
Debt instrument maturity date					Jun. 1, 2019	Jun. 1, 2019
5.25% Senior Notes due 2024
Debt Instrument [Line Items]
Debt instrument, stated interest rate				5.25%	5.25%		5.25%
Debt instrument maturity date			Jun. 15, 2024		Jun. 15, 2024
Securitization Program
Debt Instrument [Line Items]
Debt instrument, stated interest rate				0.94%	0.94%

Borrowings Fair value of long t

Borrowings Fair value of long term debt (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Fair Value Measurements [Line Items]
Fair value of debt	$ 1,614,562	$ 1,480,028
Level 1
Fair Value Measurements [Line Items]
Fair value of debt	878,638	1,024,806
Level 2
Fair Value Measurements [Line Items]
Fair value of debt	$ 735,924	$ 455,222

Financial instruments - additio

Financial instruments - additional information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014	Dec. 31, 2014
Derivatives Fair Value [Line Items]
Ineffectiveness related to derivatives	$ 0	$ 0	$ 0	$ 0
Amount of gains in accumulated other comprehensive income to be reclassified as expense to the statement of income	800,000		800,000
Allowance for doubtful accounts	9,200,000		9,200,000		$ 8,800,000
Current portion of allowance for doubtful accounts	2,700,000		2,700,000		2,400,000
Noncurrent portion of allowance for doubtful accounts	6,500,000		6,500,000		6,400,000
Net revenues	452,045,000	$ 468,105,000	881,475,000	906,651,000
Spain, Italy, Portugal, and Greece
Derivatives Fair Value [Line Items]
Current portion of allowance for doubtful accounts	7,700,000		7,700,000		8,100,000
Net revenues			66,200,000	$ 79,600,000
Foreign Currency Forward Contract
Derivatives Fair Value [Line Items]
Total notional amount for all open foreign currency forward contracts	$ 99,800,000		$ 99,800,000		$ 0
Derivative duration			9 months

Financial instruments Fair valu

Financial instruments Fair values of derivative instruments designated as hedging instruments (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Derivatives Fair Value [Line Items]
Total asset derivatives	$ 419	$ 0
Total liability derivatives	1,808	0
Foreign Currency Forward Contract | Prepaid Expenses and Other Current Assets
Derivatives Fair Value [Line Items]
Total asset derivatives	419	0
Foreign Currency Forward Contract | Other Current Liabilities
Derivatives Fair Value [Line Items]
Total liability derivatives	$ 1,808	$ 0

Financial instruments After tax

Financial instruments After tax (gain)/loss reclassified from accumulated other comprehensive income into income (Details) - Cash Flow Hedging - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Derivatives qualifying as hedges, net of tax	$ (803)	$ 73	$ (759)	$ 143
Foreign Currency Forward Contract
Derivative Instruments, Gain (Loss) [Line Items]
Derivatives qualifying as hedges, net of tax	$ (803)	$ 73	$ (759)	$ 143

Financial instruments Aggregate

Financial instruments Aggregate accounts receivable, net of allowance for doubtful accounts (Details) - USD ($) $ in Thousands		6 Months Ended	12 Months Ended
		Jun. 28, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long term accounts receivable, allowances		$ 2,700	$ 2,400
Spain, Italy, Portugal, and Greece
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current and long-term accounts receivable (net of allowances of $7.7 million and $8.1 million at June 28, 2015 and December 31, 2014, respectively) in Greece, Italy, Spain and Portugal (1)	[1]	$ 76,384	$ 76,190
Percentage of total net current and long-term accounts receivable - Greece, Italy, Spain and Portugal		26.50%	27.30%
Current and long term accounts receivable, allowances		$ 7,700	$ 8,100
Long-term portion of accounts receivable, net		$ 9,100	$ 11,300
[1]	June 28, 2015 and December 31, 2014 was $9.1 million and

Fair value measurement - additi

Fair value measurement - additional information (Detail) - USD ($)	3 Months Ended	6 Months Ended
	Jun. 28, 2015	Jun. 28, 2015	Dec. 31, 2014
Fair Value Measurements [Line Items]
Contingent consideration liability	$ 3,000,000	$ 3,000,000
Fair value measurement with unobservable inputs reconciliations liability value	27,150,000	27,150,000	$ 33,433,000
Current portion of contingent consideration	5,802,000	5,802,000	$ 11,276,000
Fair value measurement with unobservable inputs reconciliations other liabilities	21,400,000	21,400,000
Minimum
Fair Value Measurements [Line Items]
Fair value of contingent consideration liability associated with future milestone	11,000,000	11,000,000
Maximum
Fair Value Measurements [Line Items]
Fair value of contingent consideration liability associated with future milestone	$ 63,963,000	$ 63,963,000

Fair value measurement Financia

Fair value measurement Financial assets and liabilities carried at fair value measured on recurring basis (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	$ 6,960	$ 6,863
Derivative assets	419
Derivative liabilities	1,808
Contingent consideration liabilities	27,150	33,433
Quoted prices in active markets (Level 1)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	6,960	6,863
Derivative assets	0
Derivative liabilities	0
Contingent consideration liabilities	0	0
Significant other observable Inputs (Level 2)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	419
Derivative liabilities	1,808
Contingent consideration liabilities	0	0
Significant unobservable Inputs (Level 3)
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]
Investments in marketable securities	0	0
Derivative assets	0
Derivative liabilities	0
Contingent consideration liabilities	$ 27,150	$ 33,433

Fair value measurement Reconcil

Fair value measurement Reconciliation of changes in three financial liabilities measured at fair value on recurring basis (Details) $ in Thousands	6 Months Ended
	Jun. 28, 2015USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 33,433
Payment	(4,000)
Revaluations	(2,283)
Ending balance	$ 27,150

Fair value measurement Valuatio

Fair value measurement Valuation technique and inputs used to determine fair value of assets or liabilities (Details) - Jun. 28, 2015 - USD ($) $ in Millions	Total	Total
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration liability	$ 3	$ 3
Probability Of Payment
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration, weighted average		57.30%
Probability Of Payment | Minimum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration		0.00%
Probability Of Payment | Maximum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration		100.00%
Market Approach Valuation Technique [Member]
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration, weighted average		7.70%
Market Approach Valuation Technique [Member] | Minimum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration		1.60%
Market Approach Valuation Technique [Member] | Maximum
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]
Contingent consideration		10.00%

Changes in shareholders' equi58

Changes in shareholders' equity - additional information (Details) - USD ($) $ / shares in Units, shares in Millions	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014	Dec. 31, 2007
Shareholders Equity [Line Items]
Repurchase of outstanding common stock, authorized amount					$ 300,000,000
Debt instrument, stated interest rate	3.875%	3.875%	3.875%	3.875%
Equity Option
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share	5.6	6.4	5.7	6.5
Convertible Note
Shareholders Equity [Line Items]
Weighted average antidilutive which were not included in the calculation of earnings per share	3.3	2.7	3.2	2.6
Per share market price of common stock	$ 61.32		$ 61.32
Strike price of warrents			$ 74.65
Conversion of convertible notes, shares issued upon conversion	2.7	1.9	2.5	1.7

Changes in shareholders' equi59

Changes in shareholders' equity Reconciliation of basic to diluted weighted average common shares outstanding (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Equity [Abstract]
Basic (in shares)	41,560	41,380	41,514	41,321
Dilutive effect of share-based awards (in shares)	473	413	470	442
Dilutive effect of 3.875% Convertible Notes and warrants (in shares)	6,048	4,599	5,704	4,308
Diluted (in shares)	48,081	46,392	47,688	46,071

Changes in shareholders' equi60

Changes in shareholders' equity Change in accumulated other comprehensive income , net of tax (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	$ (260,895)	$ (110,855)
Other comprehensive income (loss) before reclassifications	(62,515)	5,199
Amounts reclassified from accumulated other comprehensive (loss) income	2,300	1,408
Net current-period other comprehensive income (loss)	(60,215)	6,607
Ending balance, accumulated other comprehensive income (loss)	(321,110)	(104,248)
Cash Flow Hedges
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	0	0
Other comprehensive income (loss) before reclassifications	(922)	233
Amounts reclassified from accumulated other comprehensive (loss) income	163	(90)
Net current-period other comprehensive income (loss)	(759)	143
Ending balance, accumulated other comprehensive income (loss)	(759)	143
Pension and Other Postretirement Benefits Plans
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	(141,744)	(97,037)
Other comprehensive income (loss) before reclassifications	300	(256)
Amounts reclassified from accumulated other comprehensive (loss) income	2,137	1,498
Net current-period other comprehensive income (loss)	2,437	1,242
Ending balance, accumulated other comprehensive income (loss)	(139,307)	(95,795)
Foreign Currency Translation Adjustment
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning balance, accumulated other comprehensive income (loss)	(119,151)	(13,818)
Other comprehensive income (loss) before reclassifications	(61,893)	5,222
Amounts reclassified from accumulated other comprehensive (loss) income	0	0
Net current-period other comprehensive income (loss)	(61,893)	5,222
Ending balance, accumulated other comprehensive income (loss)	$ (181,044)	$ (8,596)

Changes in shareholders' equi61

Changes in shareholders' equity Accumulated other comprehensive income into income expense (Details) - Reclassification out of Accumulated Other Comprehensive Income - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold		$ 218,808	$ 224,017	$ 425,601	$ 441,404
Income from continuing operations before taxes		50,479	58,836	99,084	102,639
Tax benefit (expense)		(5,280)	(10,006)	(14,612)	(18,540)
Income from continuing operations		45,199	48,830	84,472	84,099
Income from continuing operations		1,403	668	2,300	1,408
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes		472	(52)	263	(129)
Tax benefit (expense)		(110)	5	(100)	39
Income from continuing operations		362	(47)	163	(90)
Pension and Other Postretirement Benefits Plans
Accumulated Other Comprehensive Income (Loss) [Line Items]
Income from continuing operations before taxes		1,605	1,097	3,211	2,194
Tax benefit (expense)		(564)	(382)	(1,074)	(696)
Income from continuing operations		1,041	715	2,137	1,498
Actuarial losses	[1]	1,605	1,103	3,211	2,205
Prior-service costs	[1]	0	(6)	0	(11)
Commodity Contract | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Cost of goods sold		$ 472	$ (52)	$ 263	$ (129)
[1]	These accumulated other comprehensive income (loss) components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes on income from continui62

Taxes on income from continuing operations- additional information (Details)	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate	10.50%	17.00%	14.70%	18.10%

Pension and other postretirem63

Pension and other postretirement benefits - Additional Information (Detail) - Jun. 28, 2015 - USD ($) $ in Millions	Total	Total
Compensation and Retirement Disclosure [Abstract]
Expected employer contribution for current year		$ 2.9
Employer contribution to pension plan	$ 0.5	$ 1.7

Pension and other postretirem64

Pension and other postretirement benefits Net benefit cost of pension and postretirement benefit plans (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Pension
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 469	$ 447	$ 940	$ 897
Interest cost	4,485	4,486	8,971	8,969
Expected return on plan assets	(6,427)	(6,264)	(12,852)	(12,524)
Net amortization and deferral	1,528	1,070	3,058	2,141
Net benefit expense (income)	55	(261)	117	(517)
Other Postretirement Benefits
Defined Benefit Plan Disclosure [Line Items]
Service cost	107	138	214	276
Interest cost	511	596	1,023	1,193
Expected return on plan assets	0	0	0	0
Net amortization and deferral	78	27	155	53
Net benefit expense (income)	$ 696	$ 761	$ 1,392	$ 1,522

Commitments and contingent li65

Commitments and contingent liabilities - Additional Information (Detail) - USD ($)	Dec. 05, 2014	Jun. 28, 2015
Loss Contingencies [Line Items]
Estimated litigation liability		$ 2,600,000
Parish of Calcasieu | Judicial Ruling | Compensatory Damages
Loss Contingencies [Line Items]
Damages awarded	$ 100,000
Parish of Calcasieu | Judicial Ruling | Punitive Damages
Loss Contingencies [Line Items]
Damages awarded	$ 23,000,000
Parish of Calcasieu | Judicial Ruling | Unfavorable Regulatory Action
Loss Contingencies [Line Items]
Possible loss		10,000,000
Discontinued Operations
Loss Contingencies [Line Items]
Estimated litigation liability		$ 1,500,000
Minimum
Loss Contingencies [Line Items]
Time-frame over which the accrued amounts may be paid out, in years		15 years
Maximum
Loss Contingencies [Line Items]
Time-frame over which the accrued amounts may be paid out, in years		20 years
Accrued Liabilities
Loss Contingencies [Line Items]
Waste disposed accrued liability		$ 900,000
Other Liability
Loss Contingencies [Line Items]
Waste disposed accrued liability		$ 6,800,000

Business segment information -

Business segment information - additional information (Details) $ in Thousands		Apr. 01, 2015segment	Jun. 28, 2015USD ($)	Jun. 29, 2014USD ($)	Jun. 28, 2015USD ($)segment	Jun. 29, 2014USD ($)	Dec. 31, 2014USD ($)
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments | segment					6
Revenue			$ 452,045	$ 468,105	$ 881,475	$ 906,651
Operating profit			76,986	74,752	142,594	133,772
Depreciation and amortization			30,782	32,402	60,632	63,815
Property, plant and equipment, net			315,536		315,536		$ 317,435
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			238,518	228,349	469,724	444,810
Property, plant and equipment, net			177,772		177,772		174,893
Other Americas
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			15,122	15,187	28,563	29,959
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			143,692	174,193	284,375	342,967
Malaysia
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net			35,594		35,594		36,427
Czech Republic
Revenues from External Customers and Long-Lived Assets [Line Items]
Property, plant and equipment, net			33,612		33,612		35,655
All Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			54,713	50,376	98,813	88,915
Property, plant and equipment, net			68,558		68,558		$ 70,460
Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	[1]		96,319	96,474	179,973	178,191
Unallocated expenses
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit	[2]		(19,333)	(21,722)	(37,379)	(44,419)
Anesthesia Respiratory North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Number of operating segments as result of split | segment		2
Vascular North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			81,165	77,203	161,931	152,062
Depreciation and amortization			9,265	9,061	18,413	17,932
Vascular North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			17,055	13,544	32,805	25,709
Anesthesia North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			45,579	45,730	91,028	88,982
Depreciation and amortization			1,552	3,111	3,194	6,355
Anesthesia North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			11,434	8,399	21,394	15,364
Surgical North America
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			40,520	37,969	78,579	73,200
Depreciation and amortization			2,348	1,666	4,826	4,035
Surgical North America | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			14,315	14,366	26,642	24,914
EMEA
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			129,132	154,670	258,414	304,915
Depreciation and amortization			8,342	9,673	16,240	18,610
EMEA | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			19,343	30,080	45,678	56,961
Asia
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			62,042	62,539	110,571	112,141
Depreciation and amortization			3,010	2,305	5,408	4,143
Asia | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			18,951	17,096	27,097	29,933
OEM
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			37,918	36,610	72,633	69,792
Depreciation and amortization			1,704	1,608	3,371	3,064
OEM | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			8,366	8,296	16,409	14,900
All Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue			55,689	53,384	108,319	105,559
Depreciation and amortization			4,561	4,978	9,180	9,676
All Other | Operating Segments
Revenues from External Customers and Long-Lived Assets [Line Items]
Operating profit			$ 6,855	$ 4,693	$ 9,948	$ 10,410
[1]	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
[2]	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and impairment charges.

Condensed consolidating guara67

Condensed consolidating guarantor financial information - additional information (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 26, 2011
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate	3.875%	3.875%
Ownership percentage of subsidiaries	100.00%
Net cash (used in) provided by operating activities from continuing operations	$ 109,588	$ 120,161
Intercompany dividends paid	0
6.875% Senior Subordinated Notes due 2019
Condensed Financial Statements Captions [Line Items]
6.875% Senior Subordinated Notes due 2019			$ 250,000
5.25% Senior Subordinated Notes Due 2024
Condensed Financial Statements Captions [Line Items]
Debt instrument, stated interest rate			5.25%
Consolidation, Eliminations
Condensed Financial Statements Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	(2,360)	(3,135)
Intercompany dividends received		0
Intercompany dividends paid	2,360	3,135
Non-Guarantor Subsidiaries
Condensed Financial Statements Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations	140,720	(105,302)
Intercompany dividends received		0
Intercompany dividends paid	$ (2,360)	(3,135)
Scenario, Previously Reported | Consolidation, Eliminations
Condensed Financial Statements Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations		(74,045)
Intercompany dividends received		(229,782)
Intercompany dividends paid		303,827
Scenario, Previously Reported | Non-Guarantor Subsidiaries
Condensed Financial Statements Captions [Line Items]
Net cash (used in) provided by operating activities from continuing operations		(33,864)
Intercompany dividends received		229,782
Intercompany dividends paid		$ (303,827)

Condensed consolidating guara68

Condensed consolidating guarantor financial information Condensed consolidating statements of income and comprehensive income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014	Jun. 28, 2015	Jun. 29, 2014
Condensed Income Statements, Captions [Line Items]
Net revenues	$ 452,045	$ 468,105	$ 881,475	$ 906,651
Cost of goods sold	218,808	224,017	425,601	441,404
Gross profit	233,237	244,088	455,874	465,247
Selling, general and administrative expenses	142,228	146,843	281,925	287,140
Research and development expenses	13,443	14,870	26,327	28,932
Restructuring and impairment charges	580	7,623	5,028	15,403
Income from continuing operations before interest, extinguishment of debt and taxes	76,986	74,752	142,594	133,772
Interest, net	16,053	15,916	33,056	31,133
Interest income	154	146	323	333
Loss on extinguishment of debt, net	10,454	0	10,454	0
Income from continuing operations before taxes	50,479	58,836	99,084	102,639
(Benefit) taxes on income from continuing operations	5,280	10,006	14,612	18,540
Equity in net income of consolidated subsidiaries	0	0	0	0
Income from continuing operations	45,199	48,830	84,472	84,099
Operating loss from discontinued operations	(145)	(1,594)	(644)	(1,619)
Taxes on loss from discontinued operations	45	(469)	249	(369)
Loss from discontinued operations	(190)	(1,125)	(893)	(1,250)
Net income	45,009	47,705	83,579	82,849
Less: Income from continuing operations attributable to noncontrolling interests	446	453	664	639
Net income attributable to common shareholders	44,563	47,252	82,915	82,210
Other comprehensive income attributable to common shareholders	20,986	1,862	(60,215)	6,607
Comprehensive income attributable to common shareholders	65,549	49,114	22,700	88,817
Consolidation, Eliminations
Condensed Income Statements, Captions [Line Items]
Net revenues	(93,916)	(139,826)	(187,548)	(212,142)
Cost of goods sold	(92,265)	(129,020)	(181,416)	(201,874)
Gross profit	(1,651)	(10,806)	(6,132)	(10,268)
Selling, general and administrative expenses	(243)	108	(83)	311
Research and development expenses	0	0	0	0
Restructuring and impairment charges	0	0	0	0
Income from continuing operations before interest, extinguishment of debt and taxes	(1,408)	(10,914)	(6,049)	(10,579)
Interest, net	0		0
Loss on extinguishment of debt, net	0		0
Income from continuing operations before taxes	(1,408)	(10,914)	(6,049)	(10,579)
(Benefit) taxes on income from continuing operations	(159)	(2,163)	(1,270)	(4,259)
Equity in net income of consolidated subsidiaries	(131,332)	(136,150)	(260,657)	(243,476)
Income from continuing operations	(132,581)	(144,901)	(265,436)	(249,796)
Operating loss from discontinued operations	0	0	0	0
Taxes on loss from discontinued operations	0	0	0	0
Loss from discontinued operations	0	0	0	0
Net income	(132,581)	(144,901)	(265,436)	(249,796)
Less: Income from continuing operations attributable to noncontrolling interests	0	0	0	0
Net income attributable to common shareholders	(132,581)	(144,901)	(265,436)	(249,796)
Other comprehensive income attributable to common shareholders	(69,355)	8,591	137,134	(10,349)
Comprehensive income attributable to common shareholders	(201,936)	(136,310)	(128,302)	(260,145)
Parent Company
Condensed Income Statements, Captions [Line Items]
Net revenues	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	8,663	11,025	20,115	21,803
Research and development expenses	0	0	0	0
Restructuring and impairment charges	0	0	0	0
Income from continuing operations before interest, extinguishment of debt and taxes	(8,663)	(11,025)	(20,115)	(21,803)
Interest, net	33,358	35,155	67,718	68,881
Loss on extinguishment of debt, net	10,454		10,454
Income from continuing operations before taxes	(52,475)	(46,180)	(98,287)	(90,684)
(Benefit) taxes on income from continuing operations	(17,941)	(15,710)	(33,234)	(31,130)
Equity in net income of consolidated subsidiaries	79,246	78,802	148,784	142,926
Income from continuing operations	44,712	48,332	83,731	83,372
Operating loss from discontinued operations	(145)	(1,594)	(648)	(1,619)
Taxes on loss from discontinued operations	4	(514)	168	(457)
Loss from discontinued operations	(149)	(1,080)	(816)	(1,162)
Net income	44,563	47,252	82,915	82,210
Less: Income from continuing operations attributable to noncontrolling interests	0	0	0	0
Net income attributable to common shareholders	44,563	47,252	82,915	82,210
Other comprehensive income attributable to common shareholders	20,986	1,862	(60,215)	6,607
Comprehensive income attributable to common shareholders	65,549	49,114	22,700	88,817
Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	269,703	290,280	533,864	552,705
Cost of goods sold	158,718	176,028	317,044	328,396
Gross profit	110,985	114,252	216,820	224,309
Selling, general and administrative expenses	82,844	76,575	167,112	157,970
Research and development expenses	4,894	12,885	16,021	24,895
Restructuring and impairment charges	591	8,679	4,330	8,491
Income from continuing operations before interest, extinguishment of debt and taxes	22,656	16,113	29,357	32,953
Interest, net	(18,565)	(20,740)	(37,134)	(40,647)
Loss on extinguishment of debt, net	0		0
Income from continuing operations before taxes	41,221	36,853	66,491	73,600
(Benefit) taxes on income from continuing operations	14,917	13,535	25,909	30,753
Equity in net income of consolidated subsidiaries	51,964	57,250	111,654	100,358
Income from continuing operations	78,268	80,568	152,236	143,205
Operating loss from discontinued operations	0	0	0	0
Taxes on loss from discontinued operations	0	0	0	0
Loss from discontinued operations	0	0	0	0
Net income	78,268	80,568	152,236	143,205
Less: Income from continuing operations attributable to noncontrolling interests	0	0	0	0
Net income attributable to common shareholders	78,268	80,568	152,236	143,205
Other comprehensive income attributable to common shareholders	45,015	(2,607)	(61,746)	4,621
Comprehensive income attributable to common shareholders	123,283	77,961	90,490	147,826
Non-Guarantor Subsidiaries
Condensed Income Statements, Captions [Line Items]
Net revenues	276,258	317,651	535,159	566,088
Cost of goods sold	152,355	177,009	289,973	314,882
Gross profit	123,903	140,642	245,186	251,206
Selling, general and administrative expenses	50,964	59,135	94,781	107,056
Research and development expenses	8,549	1,985	10,306	4,037
Restructuring and impairment charges	(11)	(1,056)	698	6,912
Income from continuing operations before interest, extinguishment of debt and taxes	64,401	80,578	139,401	133,201
Interest, net	1,260	1,501	2,472	2,899
Loss on extinguishment of debt, net	0		0
Income from continuing operations before taxes	63,141	79,077	136,929	130,302
(Benefit) taxes on income from continuing operations	8,463	14,344	23,207	23,176
Equity in net income of consolidated subsidiaries	122	98	219	192
Income from continuing operations	54,800	64,831	113,941	107,318
Operating loss from discontinued operations	0	0	4	0
Taxes on loss from discontinued operations	41	45	81	88
Loss from discontinued operations	(41)	(45)	(77)	(88)
Net income	54,759	64,786	113,864	107,230
Less: Income from continuing operations attributable to noncontrolling interests	446	453	664	639
Net income attributable to common shareholders	54,313	64,333	113,200	106,591
Other comprehensive income attributable to common shareholders	24,340	(5,984)	(75,388)	5,728
Comprehensive income attributable to common shareholders	$ 78,653	$ 58,349	$ 37,812	$ 112,319

Condensed consolidating guara69

Condensed consolidating guarantor financial information Condensed consolidating balance sheets (Details) - USD ($) $ in Thousands	Jun. 28, 2015	Dec. 31, 2014	Jun. 29, 2014	Dec. 31, 2013
Current assets
Cash and cash equivalents	$ 325,010	$ 303,236	$ 237,382	$ 431,984
Accounts receivable, net	286,371	273,704
Accounts receivable from consolidated subsidiaries	0	0
Inventories, net	347,095	335,593
Prepaid expenses and other current assets	34,659	35,697
Prepaid taxes	46,008	40,256
Deferred tax assets	56,294	57,301
Assets held for sale	7,072	7,422
Total current assets	1,102,509	1,053,209
Property, plant and equipment, net	315,536	317,435
Goodwill	1,317,874	1,323,553
Intangible assets, net	1,185,517	1,216,720
Investments in affiliates	401	1,150
Deferred tax assets	1,134	1,178
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	61,191	64,010
Total assets	3,984,162	3,977,255
Current liabilities
Current borrowings	415,991	368,401
Accounts payable	74,364	64,100
Accounts payable to consolidated subsidiaries	0	0
Accrued expenses	65,843	72,383
Current portion of contingent consideration	5,802	11,276
Payroll and benefit-related liabilities	69,564	85,442
Accrued interest	7,991	9,169
Income taxes payable	11,700	13,768
Other current liabilities	10,631	10,360
Total current liabilities	661,886	634,899
Long-term borrowings	696,000	700,000
Deferred tax liabilities	433,257	451,541
Pension and other postretirement benefit liabilities	161,036	167,241
Noncurrent liability for uncertain tax positions	50,547	50,884
Notes payable and other amounts due from consolidated subsidiaries	0	0
Other liabilities	61,429	58,991
Total liabilities	2,064,155	2,063,556
Total common shareholders' equity	1,917,779	1,911,309
Noncontrolling interest	2,228	2,390
Total equity	1,920,007	1,913,699	1,984,379	1,916,016
Total liabilities and equity	3,984,162	3,977,255
Consolidation, Eliminations
Current assets
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	3,938	3,855
Accounts receivable from consolidated subsidiaries	(2,524,702)	(2,612,090)
Inventories, net	(28,977)	(23,286)
Prepaid expenses and other current assets	3,509	3,508
Prepaid taxes	0	0
Deferred tax assets	0	0
Assets held for sale	0	0
Total current assets	(2,546,232)	(2,628,013)
Property, plant and equipment, net	0	0
Goodwill	0	0
Intangible assets, net	0	0
Investments in affiliates	(6,989,606)	(7,060,092)
Deferred tax assets	(54,331)	(56,601)
Notes receivable and other amounts due from consolidated subsidiaries	(2,760,597)	(2,499,680)
Other assets	0	0
Total assets	(12,350,766)	(12,244,386)
Current liabilities
Current borrowings	0	0
Accounts payable	0	0
Accounts payable to consolidated subsidiaries	(2,524,702)	(2,612,090)
Accrued expenses	0	0
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	0	0
Accrued interest	0	0
Income taxes payable	(1,136)	134
Other current liabilities	0	0
Total current liabilities	(2,525,838)	(2,611,956)
Long-term borrowings	0	0
Deferred tax liabilities	(54,330)	(56,600)
Pension and other postretirement benefit liabilities	0	0
Noncurrent liability for uncertain tax positions	0	0
Notes payable and other amounts due from consolidated subsidiaries	(2,760,597)	(2,499,680)
Other liabilities	0	0
Total liabilities	(5,340,765)	(5,168,236)
Total common shareholders' equity	(7,010,001)	(7,076,150)
Noncontrolling interest	0	0
Total equity	(7,010,001)	(7,076,150)
Total liabilities and equity	(12,350,766)	(12,244,386)
Parent Company
Current assets
Cash and cash equivalents	26,063	27,996	31,283	42,749
Accounts receivable, net	2,521	2,346
Accounts receivable from consolidated subsidiaries	13,805	35,996
Inventories, net	0	0
Prepaid expenses and other current assets	12,261	14,301
Prepaid taxes	27,334	23,493
Deferred tax assets	30,683	30,248
Assets held for sale	2,901	2,901
Total current assets	115,568	137,281
Property, plant and equipment, net	3,249	3,489
Goodwill	0	0
Intangible assets, net	0	0
Investments in affiliates	5,565,400	5,680,328
Deferred tax assets	51,481	52,244
Notes receivable and other amounts due from consolidated subsidiaries	1,187,753	1,009,686
Other assets	27,216	27,999
Total assets	6,950,667	6,911,027
Current liabilities
Current borrowings	370,091	363,701
Accounts payable	2,369	1,449
Accounts payable to consolidated subsidiaries	2,284,828	2,259,891
Accrued expenses	16,231	17,149
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	20,696	20,693
Accrued interest	7,971	9,152
Income taxes payable	0	0
Other current liabilities	1,851	5
Total current liabilities	2,704,037	2,672,040
Long-term borrowings	696,000	700,000
Deferred tax liabilities	0	0
Pension and other postretirement benefit liabilities	106,789	110,830
Noncurrent liability for uncertain tax positions	12,099	11,431
Notes payable and other amounts due from consolidated subsidiaries	1,492,235	1,483,984
Other liabilities	21,728	21,433
Total liabilities	5,032,888	4,999,718
Total common shareholders' equity	1,917,779	1,911,309
Noncontrolling interest	0	0
Total equity	1,917,779	1,911,309
Total liabilities and equity	6,950,667	6,911,027
Guarantor Subsidiaries
Current assets
Cash and cash equivalents	298	0	3,235	14,500
Accounts receivable, net	2,785	2,422
Accounts receivable from consolidated subsidiaries	2,230,679	2,303,284
Inventories, net	207,099	204,335
Prepaid expenses and other current assets	4,897	4,786
Prepaid taxes	0	0
Deferred tax assets	16,408	17,387
Assets held for sale	0	0
Total current assets	2,462,166	2,532,214
Property, plant and equipment, net	173,196	170,054
Goodwill	704,858	703,663
Intangible assets, net	727,859	743,222
Investments in affiliates	1,403,623	1,359,661
Deferred tax assets	0	0
Notes receivable and other amounts due from consolidated subsidiaries	1,572,844	1,489,994
Other assets	7,287	6,801
Total assets	7,051,833	7,005,609
Current liabilities
Current borrowings	0	0
Accounts payable	34,416	32,692
Accounts payable to consolidated subsidiaries	197,490	188,908
Accrued expenses	20,341	21,479
Current portion of contingent consideration	5,802	11,276
Payroll and benefit-related liabilities	16,054	27,228
Accrued interest	0	0
Income taxes payable	0	0
Other current liabilities	3,225	3,065
Total current liabilities	277,328	284,648
Long-term borrowings	0	0
Deferred tax liabilities	444,282	462,274
Pension and other postretirement benefit liabilities	34,917	35,074
Noncurrent liability for uncertain tax positions	15,694	15,569
Notes payable and other amounts due from consolidated subsidiaries	1,087,952	915,163
Other liabilities	26,717	24,900
Total liabilities	1,886,890	1,737,628
Total common shareholders' equity	5,164,943	5,267,981
Noncontrolling interest	0	0
Total equity	5,164,943	5,267,981
Total liabilities and equity	7,051,833	7,005,609
Non-Guarantor Subsidiaries
Current assets
Cash and cash equivalents	298,649	275,240	$ 202,864	$ 374,735
Accounts receivable, net	277,127	265,081
Accounts receivable from consolidated subsidiaries	280,218	272,810
Inventories, net	168,973	154,544
Prepaid expenses and other current assets	13,992	13,102
Prepaid taxes	18,674	16,763
Deferred tax assets	9,203	9,666
Assets held for sale	4,171	4,521
Total current assets	1,071,007	1,011,727
Property, plant and equipment, net	139,091	143,892
Goodwill	613,016	619,890
Intangible assets, net	457,658	473,498
Investments in affiliates	20,984	21,253
Deferred tax assets	3,984	5,535
Notes receivable and other amounts due from consolidated subsidiaries	0	0
Other assets	26,688	29,210
Total assets	2,332,428	2,305,005
Current liabilities
Current borrowings	45,900	4,700
Accounts payable	37,579	29,959
Accounts payable to consolidated subsidiaries	42,384	163,291
Accrued expenses	29,271	33,755
Current portion of contingent consideration	0	0
Payroll and benefit-related liabilities	32,814	37,521
Accrued interest	20	17
Income taxes payable	12,836	13,634
Other current liabilities	5,555	7,290
Total current liabilities	206,359	290,167
Long-term borrowings	0	0
Deferred tax liabilities	43,305	45,867
Pension and other postretirement benefit liabilities	19,330	21,337
Noncurrent liability for uncertain tax positions	22,754	23,884
Notes payable and other amounts due from consolidated subsidiaries	180,410	100,533
Other liabilities	12,984	12,658
Total liabilities	485,142	494,446
Total common shareholders' equity	1,845,058	1,808,169
Noncontrolling interest	2,228	2,390
Total equity	1,847,286	1,810,559
Total liabilities and equity	$ 2,332,428	$ 2,305,005

Condensed consolidating guara70

Condensed consolidating guarantor financial information Condensed consolidating statements of cash flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 28, 2015	Jun. 29, 2014
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	$ 109,588	$ 120,161
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	(31,321)	(30,850)
Proceeds from sale of assets and investments	0	4,139
Payments for businesses and intangibles acquired, net of cash acquired	(37,559)	(28,535)
Investments in affiliates	0	(60)
Net cash used in investing activities from continuing operations	(68,880)	(55,306)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from new borrowings	288,100	250,000
Repayment of long-term borrowings	(250,981)	(480,000)
Debt extinguishment, issuance and amendment fees	(8,746)	(3,275)
Payments to noncontrolling interest shareholders	(832)	(1,094)
Net proceeds from share based compensation plans and the related tax impacts	4,843	2,391
Payments for contingent consideration	(3,989)	0
Dividends	(28,234)	(28,093)
Intercompany transactions	0	0
Intercompany dividends paid	0
Net cash provided by (used in) financing activities from continuing operations	161	(260,071)
Cash Flows from Discontinued Operations:
Net cash used in operating activities	(1,363)	(1,531)
Net cash used in discontinued operations	(1,363)	(1,531)
Effect of exchange rate changes on cash and cash equivalents	(17,732)	2,145
Net increase (decrease) in cash and cash equivalents	21,774	(194,602)
Cash and cash equivalents at the beginning of the period	303,236	431,984
Cash and cash equivalents at the end of the period	325,010	237,382
Consolidation, Eliminations
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	(2,360)	(3,135)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	0	0
Proceeds from sale of assets and investments		0
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates		0
Intercompany dividends received		0
Net cash used in investing activities from continuing operations	0	0
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from new borrowings	0	0
Repayment of long-term borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Payments to noncontrolling interest shareholders	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0
Dividends	0	0
Intercompany transactions	0	0
Intercompany dividends paid	2,360	3,135
Net cash provided by (used in) financing activities from continuing operations	2,360	3,135
Cash Flows from Discontinued Operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	(92,490)	(49,308)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	(108)	(2,019)
Proceeds from sale of assets and investments		1,669
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates		(60)
Net cash used in investing activities from continuing operations	(108)	(410)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from new borrowings	288,100	250,000
Repayment of long-term borrowings	(250,981)	(480,000)
Debt extinguishment, issuance and amendment fees	(8,746)	(3,275)
Payments to noncontrolling interest shareholders	0	0
Net proceeds from share based compensation plans and the related tax impacts	4,843	2,391
Payments for contingent consideration	0
Dividends	(28,234)	(28,093)
Intercompany transactions	86,197	298,760
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	91,179	39,783
Cash Flows from Discontinued Operations:
Net cash used in operating activities	(514)	(1,531)
Net cash used in discontinued operations	(514)	(1,531)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	(1,933)	(11,466)
Cash and cash equivalents at the beginning of the period	27,996	42,749
Cash and cash equivalents at the end of the period	26,063	31,283
Guarantor Subsidiaries
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	63,718	277,906
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	(17,339)	(14,080)
Proceeds from sale of assets and investments		2,470
Payments for businesses and intangibles acquired, net of cash acquired	(4,348)	0
Investments in affiliates		0
Net cash used in investing activities from continuing operations	(21,687)	(11,610)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from new borrowings	0	0
Repayment of long-term borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Payments to noncontrolling interest shareholders	0	0
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	(3,989)
Dividends	0	0
Intercompany transactions	(37,744)	(277,561)
Intercompany dividends paid	0	0
Net cash provided by (used in) financing activities from continuing operations	(41,733)	(277,561)
Cash Flows from Discontinued Operations:
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	298	(11,265)
Cash and cash equivalents at the beginning of the period	0	14,500
Cash and cash equivalents at the end of the period	298	3,235
Non-Guarantor Subsidiaries
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]
Net cash (used in) provided by operating activities from continuing operations	140,720	(105,302)
Net Cash Provided by (Used in) Investing Activities [Abstract]
Expenditures for property, plant and equipment	(13,874)	(14,751)
Proceeds from sale of assets and investments		0
Payments for businesses and intangibles acquired, net of cash acquired	(33,211)	(28,535)
Investments in affiliates		0
Intercompany dividends received		0
Net cash used in investing activities from continuing operations	(47,085)	(43,286)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from new borrowings	0	0
Repayment of long-term borrowings	0	0
Debt extinguishment, issuance and amendment fees	0	0
Payments to noncontrolling interest shareholders	(832)	(1,094)
Net proceeds from share based compensation plans and the related tax impacts	0	0
Payments for contingent consideration	0
Dividends	0	0
Intercompany transactions	(48,453)	(21,199)
Intercompany dividends paid	(2,360)	(3,135)
Net cash provided by (used in) financing activities from continuing operations	(51,645)	(25,428)
Cash Flows from Discontinued Operations:
Net cash used in operating activities	(849)	0
Net cash used in discontinued operations	(849)	0
Effect of exchange rate changes on cash and cash equivalents	(17,732)	2,145
Net increase (decrease) in cash and cash equivalents	23,409	(171,871)
Cash and cash equivalents at the beginning of the period	275,240	374,735
Cash and cash equivalents at the end of the period	$ 298,649	$ 202,864

Uncategorized Items - tfx-20150

Label	Element	Value
Goodwill, Gross	us-gaap_GoodwillGross	$ 1,650,002
Other Segments [Member]
Goodwill	us-gaap_Goodwill	114,352
Goodwill, Gross	us-gaap_GoodwillGross	141,264
Asia [Member]
Goodwill	us-gaap_Goodwill	144,712
Goodwill, Gross	us-gaap_GoodwillGross	146,188
EMEA [Member]
Goodwill	us-gaap_Goodwill	339,029
Goodwill, Gross	us-gaap_GoodwillGross	319,628
Anesthesia North America [Member]
Goodwill	us-gaap_Goodwill	129,898
Goodwill, Gross	us-gaap_GoodwillGross	226,551
Oem [Member]
Goodwill	us-gaap_Goodwill	0
Goodwill, Gross	us-gaap_GoodwillGross	1,194
Surgical North America [Member]
Goodwill	us-gaap_Goodwill	250,912
Goodwill, Gross	us-gaap_GoodwillGross	250,912
Vascular North America [Member]
Goodwill	us-gaap_Goodwill	344,650
Goodwill, Gross	us-gaap_GoodwillGross	$ 564,265